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ABSTRACT: 
 
The purpose of this study was to investigate the association of the selected MYH9 
single nucleotide polymorphisms (SNPs) with chronic kidney disease (CKD) and its 
related co-morbidities in the South African mixed ancestry population residing in 
Bellville South, Cape Town. In 2008, two landmark studies identified SNPs in the 
MYH9 gene which explained most of the increased risk for non-diabetic CKD in 
African Americans. These polymorphisms were later found to be weakly associated 
with diabetic nephropathy.  
 
Three SNPs that exhibited independent evidence for association with CKD were 
selected (rs5756152, rs4821480 and rs12107). These were genotyped using a 
Taqman genotyping assay on a BioRad MiniOpticon and confirmed by sequencing in 
724 subjects from Bellville South, Cape Town, South Africa. Prevalent CKD was 
defined based on the estimated glomerular filtration rate calculated using the  
modification of diet in renal disease (MDRD) formula. 
 
Chronic kidney disease was present in 214 subjects (29.6%), 96.3% were stage 3 
and only 8 subjects were stage 4. In additive allelic models, adjusted for age and 
gender, rs5756152 demonstrated an association with kidney function whereby each 
G allele of rs5756152 increased eGFR by 3.67 ml/min/1.73, reduced serum 
creatinine by 4.5% and increased fasting plasma glucose by 0.51 mmol/L. When an 
interaction model was used, the effect of rs5756152 on serum creatinine, eGFR and 
blood glucose levels was retained, and enhanced, but only in diabetic subjects. In 
addition, rs4821480 T allele increased eGFR while rs12107 A allele decreased 
glucose levels in diabetic subjects.  
 
In contrast to reports that MYH9 SNPs are strongly associated with non-diabetic end 
stage renal disease, our study demonstrated that rs5756152 and rs4821480 are 
associated with early kidney function derangements in type 2 diabetes whilst 
rs12107 is associated with glucose metabolism. Our findings, along with previous 
reports, suggest that the MYH9 gene may have a broader genetic risk effect on 
different types of kidney diseases than previously thought. 
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OPSOMMING: 
 
Hierdie studie het ondersoek ingestel na die verband tussen drie gekose MYH9-
enkelnukleotied-polimorfismes (SNP’s) en chroniese niersiekte (hierna ‘niersiekte’), 
wat verwante ko-morbiditeite insluit, onder ’n Suid-Afrikaanse populasie van 
gemengde afkoms in Bellville-Suid, Kaapstad. Twee rigpuntstudies het in 2008 op 
SNP’s in die MYH9-geen afgekom wat verklaar het waarom Afro-Amerikaners ’n 
hoër risiko vir niediabetiese niersiekte toon. Later is bevind dat hierdie polimorfismes 
ook ’n swak verband met diabetiese nefropatie het.  
 
Drie SNP’s wat elk onafhanklik bewys gelewer het van ’n verband met niersiekte is 
vervolgens gekies (rs5756152, rs4821480 en rs12107). Die SNP’s is daarná met 
behulp van die Taqman-toets op ’n BioRad MiniOpticon aan genotipering onderwerp, 
en is toe deur middel van reeksbepaling by 724 proefpersone van Bellville-Suid, 
Kaapstad, Suid-Afrika, bevestig. Die voorkoms van niersiekte is bepaal op grond van 
die geraamde glomerulêre filtrasietempo (eGFR), wat aan die hand van die 
‘niersiekte-dieetveranderings’- (MDRD-)formule bereken is. 
 
Daar is bevind dat 214 proefpersone (29,6%) aan chroniese niersiekte ly – 96,3% 
was in fase 3 en slegs agt proefpersone in fase 4. In toegevoegde alleliese modelle 
wat vir ouderdom en geslag aangepas is, het rs5756152 ’n verband met nierfunksie 
getoon: Elke G-allel van rs5756152 het eGFR met 3,67 ml/min/1,73 verhoog, 
serumkreatinien met 4,5% verlaag en vastende plasmaglukose met 0,51 mmol/L 
verhoog. Toe ’n interaksiemodel gebruik is, is die effek van rs5756152 op 
serumkreatinien, eGFR en bloedglukosevlakke behou en versterk, hoewel slegs by 
diabetiese proefpersone. Daarbenewens het die T-allel van rs4821480 eGFR 
verhoog, terwyl die A-allel van rs12107 ook glukosevlakke by diabetiese 
proefpersone verlaag het. 
  
In teenstelling met bewerings dat MYH9-SNP’s ’n sterk verband met niediabetiese 
eindstadiumniersiekte toon, het hierdie studie bewys dat rs5756152 en rs4821480 
met vroeë nierfunksieversteurings by tipe 2-diabetes verband hou, terwyl rs12107 
Stellenbosch University  http://scholar.sun.ac.za
 iv 
 
 
 
 
weer met glukosemetabolisme verbind word. Tesame met vorige studies, doen 
hierdie navorsingsbevindinge dus aan die hand dat die MYH9-geen dalk ’n groter 
genetiese risiko-effek op verskillende tipes niersiekte het as wat voorheen vermoed 
is.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 v 
 
 
 
 
ACKNOWLEDGEMENTS: 
 
 
I wish to thank my supervisors, Professor TE Matsha and Professor RT Erasmus, for 
their guidance and direction during this learning experience. 
 
To my mom, I thank you for your continuous support. 
 
This research was supported by a grant from the University Research Fund of the 
Cape Peninsula University of Technology, South Africa. The student received a Merit 
Bursary from Stellenbosch University, 
 
A portion of this work has been presented at the Annual Stellenbosch Academic Day 
2012 and will be presented at the International PathPoint conference on 29th 
September 2012, at Crystal Towers, Cape Town 
 
 
 
 
 
 
 
 
DEDICATIONS: 
 
 
For Papa ♥ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 vi 
 
 
 
 
TABLE OF CONTENTS 
 
Declaration           i 
Abstract           ii 
Opsomming           iii 
Acknowledgements          v 
Dedications           v 
Table of Contents          vi 
List of Figures          ix 
List of Tables          x 
List of Abbreviations         xi 
Chapter 1: Literature Review        1 
1.1 Introduction          2 
1.2      Chronic kidney disease        4 
1.2.1 CKD Definition         4 
1.2.2 Symptoms of CKD         4 
1.2.3 Diagnosis of CKD         5 
1.2.4 Classification of CKD        11 
1.2.5 Complications associated with CKD      12 
1.2.6 Treatment of CKD         12  
1.3      Epidemiology of CKD        13 
1.4      Markers for CKD progression       15 
1.4.1 Asymmetric Dimethylarginine       15 
1.4.2 Fibroblast growth factor 23        16 
1.4.3 Vitamin D          17 
1.4.4 Adiponectin          18 
1.4.5 Apolipoprotein A-IV         19 
1.4.6 Natriuretic peptides         20 
1.4.7 Neutrophil gelatinase-associated lipocalin     21 
1.4.8 Kidney injury molecule-1        21 
1.5 Aetiology of CKD         22 
1.5.1 Non-modifiable factors        22 
1.5.1.1 Age          23 
Stellenbosch University  http://scholar.sun.ac.za
 vii 
 
 
 
 
1.5.1.2 Gender          23 
1.5.1.3 Ethnicity          24 
1.5.1.4 Low birth weight         25 
1.5.1.5 Small kidney size        26 
1.5.1.6 Family history of CKD        26 
1.5.2 Lifestyle factors         26 
1.5.3 Folk medicine         30 
1.5.4 Genetic factors associated with CKD      31 
1.5.5 Nonmuscle myosin heavy chain and its association with CKD  37 
1.6 Significance of research        42 
1.7 Conclusion          43 
Chapter 2: Research Methodology       44 
2.1  Introduction          45 
2.2  Research setting         45 
2.3  Research design and study population      46 
2.4  Inclusion/Exclusions criteria       46 
2.5  Sample size          47 
2.6  Data collection         47 
2.6.1  Anthropometric measurements       48 
2.6.2 Biochemical analysis        49 
2.6.3 Data management         49 
2.7  Genetic analyses         50 
2.7.1  DNA extraction         50 
2.7.2  DNA quality          51 
2.7.3  Conventional polymerase chain reaction and sequencing   51 
2.7.4  Real time polymerase chain reaction       54 
2.8  Statistical analysis         56 
2.9  Ethical considerations        56 
2.10  Conclusion          57 
Chapter 3: Results and discussion       58 
3.1  Introduction          59 
3.2  Materials and methods        61 
3.3  Results          63 
Stellenbosch University  http://scholar.sun.ac.za
 viii 
 
 
 
 
3.3.1  Genetic analysis         63 
3.3.2  General characteristics        69 
3.3.3 Genotype distribution        71 
3.3.4 Genotype associations        75 
3.4  Discussion          77 
3.5 Recommendation for future studies      81  
Chapter 4: References         83 
Chapter 5: Addenda         104 
Addendum A – Ethical Clearance        105 
Addendum B – Main study questionnaire       107 
Addendum C – Consent form from main study      117 
Addendum D – Solutions         121 
Addendum E – Letter of permission: Nature Publishing Group License  123 
Addendum F – Letter of permission: Elsevier License     126 
 
  
Stellenbosch University  http://scholar.sun.ac.za
 ix 
 
 
 
 
LIST OF FIGURES: 
 
Figure 3.1: The schematic representation of the myosin non-muscle structure 59 
Figure 3.2: The gene structure and linkage disequilibrium plot of 49 kb of the  
MYH9 gene           60 
Figure 3.3: Conventional PCR products of the three SNPs genotypes on 2%  
agarose gel, stained by EtBr and visualized using ultraviolet light  
transillumination          64 
Figure 3.4: Sequencing chromatogram for rs575615     65 
Figure 3.5: Sequencing chromatogram for rs482480     66 
Figure 3.6: Sequencing chromatogram for rs12107     67 
Figure 3.7: Allele discrimination scatter plot showing amplification of alleles for SNP 
rs5756152           68 
Figure 3.8: Allele discrimination scatter plot showing amplification of alleles for SNP 
rs4821480           68 
Figure 3.9: Allele discrimination scatter plot showing amplification of alleles for SNP 
rs12107           69 
Figure 3.10: Minor allele frequencies of the three selected SNPs   72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 x 
 
 
 
 
LIST OF TABLES: 
 
Table 1.1: Classification of Chronic Kidney Disease     11 
Table 2.1: Oligonucleotide primers and their characteristics for amplifying  
MYH9 regions containing SNPs of interest      51 
Table 3.1: General characteristics of participants, stratified by gender  70 
Table 3.2: General characteristics of participants stratified by CKD status  71 
Table 3.3: Linkage disequilibrium data between the three selected SNPs  73 
Table 3.4: Genotype distribution, minor allele frequencies, and unadjusted  
p-values for comparing genotype distributions between CKD groups  74 
Table 3.5: Genotype distribution, minor allele frequencies, and unadjusted  
p-values for comparing genotype distributions between genders   75 
Table 3.6: Genotype association and additive allelic association p-values  
between traits and SNPs         76 
Table 3.7: Significant SNP-trait pairs in additive allelic associations between  
DM and non DM groups         76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 xi 
 
 
 
 
LIST OF ABBREVIATIONS: 
 
1.25(OH)2D – 1,25-dihydroxyvitamin D 
25(OH)D – 25-hydroxyvitamin D 
A – Adenine 
ACE – Angiotensin-Converting Enzyme 
ACR – Albumin;Creatinine Ratio 
ACTN4 – Actinin Alpha 4 
ADMA – Asymmetric Dimethylarginine 
AKI – Acute Kidney Injury 
ANP – Atrial Natriuetic Peptide 
Apo A-IV – Apolipoprotein A-IV  
APOL – Apolipoprotein 
ARPKD – Autosomal recessive polycystic kidney disease 
BLAST – Basic Alignment Search Tool 
BMI – Body Mass Index 
BNP – Brain Natriuetic Peptide 
C – Cytosine 
CEU – Europeans 
CI – Confidence Interval 
CKD – Chronic Kidney Disease 
CKD-EPI – Chronic Kidney Disease – Epidemiology Collaboration 
CUBN – Cubulin 
CVD – Cardiovascular Disease 
DBP – Diastolic Blood Pressure 
DM – Diabetes Mellitus 
DN – Diabetic Nephropathy 
DNA – Deoxyribose Nucleic Acid 
EDTA – Ethylenediamine Tetra Acetic Acid  
eGFR – Estimated Glomerular Filtration Rate  
ELMO1 – Engulfment and Cell Motility 1 
EMEA – European Medicines Agency 
ESRD – End-Stage Renal Disease 
Stellenbosch University  http://scholar.sun.ac.za
 xii 
 
 
 
 
FBG – Fasting Blood Glucose 
FDA – Food and Drug Administration  
FGF-23 – Fibroblast Growth Factor 23 
FSGS – Focal Segmental Glomerulosclerosis 
G – Guanine  
GCKD – Glomerulocystic Disease 
GFR – Glomerular Filtration Rate 
GLDH – L-Glutamate Dehydrogenase 
GWAS – Genome – Wide Association Studies 
HBA1C – Haemoglobin A1c – glycated haemoglobin  
HDL – High Dense Lipoprotein 
HDL-c – High Density Lipoprotein - Cholesterol  
H-ESRD – Hypertensive End Stage Renal Disease 
HIV – Human Immunodeficiency Virus  
HIVAN – Human Immunodeficency Virus Associated Nephropathy 
HN – Hypertensive Nepherosclerosis 
HPT – Hypertension 
HWE – Hardy-Weinberg Equilibrium  
IDT – Integrated DNA Technology  
IFG – Impaired Fasting Glucose 
IGT – Impaired Glucose Tolerance 
IL -1 – Interleukin 1 
IL-1Ra – Inter-Leukin-1 Receptor Antagonist 
INF2 – Inverted Forming 2 
IQR – Interquartile range 
KDIGO – Kidney Disease: Improving Global Outcomes 
KIM-1 – Kidney Injury Molecule 1 
LCAT – Lecithin-Cholesterol Acyltransferase 
LD – Linkage Disequilibrium 
LDL-c – Low Density Lipoprotein - Cholesterol 
LOD – Logarithm of Odds 
LPL – Lipoprotein Lipase 
MALD – Mapping of Admixture Linkage Disequilibrium 
Stellenbosch University  http://scholar.sun.ac.za
 xiii 
 
 
 
 
MDRD – Modification of Diet in Renal Disease  
MTHFR – Methenyltetrahydrofolate Reductase  
MTHFS – Methenyltetrahydrofolate Synthase 
MYH9 – Myosin Heavy Chain 9 
NCBI – National Centre for Bioinformatics Institute 
NGAL – Neutrophil Gellatinase-Associated Lipocalin 
NGSP – National Glycohameoglobin Standarisation Program 
NHANES – National Health and Nutrition Examination Survey 
NO – Nitric Oxide 
NPHS2 – Nephrosis 2 
NT-proBNP – N-Terminal prohormone Brain Natriuetic Peptide 
OGTT – Oral Glucose Tolerance Test 
OR – Odds Ratio 
PCR – Polymerase Chain Reaction 
PTH – Parathyroid Hormone 
q-PCR – Real-Time Polymerase Chain Reaction  
RAS – Renin-Angiotensin System  
RFU – Relative Fluorescence Units 
SADTR – South African Dialysis and Transplant Registry 
SBP – Systolic Blood Pressure 
SGA – Small Gestational Age 
SLE – Systemic Lupus Erythematosus  
SNP – Single Nucleotide Polymorphism 
T – Thymine 
TB – Tuberculosis 
TCF7L2 – Transcription Factor 7 Like-2 
TE – Tris EDTA 
TG – Triglycerides 
TGF-β – Transforming Growth Factor 
Tm – Melting Temperature 
TRPC6 – Transient Receptor Potential Cation Subfamily 6 
UAE – Urinary Albumin Excretion 
UMOD – Uromodulin 
Stellenbosch University  http://scholar.sun.ac.za
 xiv 
 
 
 
 
USRDS – United States Renal Data System 
UV/VIS – Ultraviolet Visible 
WHO – World Health Organization  
YRI – Yorubas 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1  
[Literature Review] 
Stellenbosch University  http://scholar.sun.ac.za
 2 
 
 
1.1 INTRODUCTION 
 
Background: 
Chromosome 22 is a widely researched chromosome in regard to gene mutation 
and disease association. Two genes mapped on chromosome 22q12 have been 
linked to the risk and progression of chronic kidney disease (CKD), the myosin 
nonmuscle heavy chain 9 (MYH9) gene and more recently, apolipoprotein 1 
(APOL1). More than 45 mutations have been found in the MYH9 gene and 
implicated in a wide range of disorders that have subsequently been grouped and 
termed the MYH9-related disorder, however the mechanisms underlying the 
cause of CKD has not yet been discovered. Chronic kidney disease is a condition 
marked by the gradual decline of kidney function over time.  
 
Many studies have found an association of MYH9 variants with an increased 
CKD risk, including focal segmented glomerulosclerosis (FSGS), hypertensive 
end stage renal disease (H-ESRD), non-diabetic end-stage renal disease 
(ESRD), HIV associated nephropathy (HIVAN) and a weak association with 
diabetic nephropathy (DN). Single nucleotide polymorphisms (SNPs) increasing 
the risk for these kidney diseases were identified in different regions of the MYH9 
gene, clustered into groups according to linkage disequilibrium (LD) blocks, E-1, 
S-1, F-1 and L1 haplotypes, with three SNPs (rs5756152, rs4821480 and 
rs12107) showing independent association with CKD.  
 
The most compelling part about the MYH9 locus is the significant and increased 
risk allele frequency in African Americans. This population is an inter-mating 
product of Africans with European Caucasians. The mixed ancestry (Coloured) 
ethnic group in South Africa is also heterogeneous with its origin, with 
predominantly African, European, and a proportion of Asian ancestry. This has 
prompted the speculation that the MYH9 gene may play a role in the 
development of CKD in the mixed ancestry population group in South Africa, and 
therefore, investigation as a predisposing factor of this disease is warranted. 
Although the magnitude of CKD in this population in South Africa is currently 
unknown due to the lack of reliable national data systems in place to collect, 
analyze and report this information; several studies have reported a high 
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prevalence of diabetes and hypertension in the mixed ancestry ethnic group. 
Diabetes, hypertension and glomerulonephritis are the three leading causes of 
CKD, and the incidence of ESRD has been observed to mirror that of these three 
disorders.  Thus the research question of this thesis is: Is there an association 
between MYH9 gene polymorphisms and CKD and its related co-morbidities 
within the mixed ancestry ethnic group of South Africa? 
 
Problem statement: 
No detailed genetic analyses of kidney diseases have been done in the mixed 
ancestry population of South Africa, and it is not known if there is an association 
between MYH9 SNPs rs4821480, rs5756152 and rs12107; and CKD and its 
related re-comorbidities. 
 
Research aim: 
The aim of this study is to determine whether or not MYH9 polymorphisms have 
an association with CKD and its related co-morbidities in the South African mixed 
ancestry population residing in Bellville South, Cape Town.  
 
Research objectives: 
The objectives of this study are to: 
 
I. Genotype both CKD and non-CKD subjects’ extracted deoxyribose 
nucleic acid (DNA) samples for MYH9 polymorphisms, namely, rs12107, 
rs4821480, rs5756152, that were shown in other populations to be 
independently associated with CKD  
II. Determine the allele and genotype frequencies of the three MYH9 
polymorphisms in the selected study population. 
III. Determine the association between MYH9 alleles and CKD and its related 
co-morbidities - obesity, type 2 diabetes mellitus and hypertension.  
 
Chapter overview: 
This chapter will cover CKD definition, diagnosis, classification and treatment; 
epidemiology, aetiology and research into CKD initiation and progression 
markers. Details into the genetics of CKD and expansion into MYH9 gene 
research will be discussed.  
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1.2 CHRONIC KIDNEY DISEASE 
 
1.2.1 CKD Definition 
 
Chronic kidney disease (CKD) is a condition marked by the gradual decline of 
kidney function over time. The ‘Kidney Disease: Improving Global Outcomes 
(KDIGO)’ defines CKD as kidney damage for greater than 3 months with or 
without a decreased glomerular filtration rate, which can lead to a lowered 
glomerular filtration rate (GFR) (Levey et al, 2005). Chronic kidney disease is 
manifested by either a pathogenic abnormality or kidney damage markers, or a 
glomerular filtration rate of less than 60 ml/min/1.73 m² for more than 3 months 
with or without kidney damage; or abnormal imaging tests (Hogg et al, 2003). 
 
1.2.2 Symptoms of CKD 
 
Symptoms may not appear until the kidney function is severely decreased but 
they include fatigue, poor concentration, a poor appetite, insomnia, muscle 
cramping at night, swollen feet and ankles, dry itchy skin, nocturia, restless legs, 
dyspnoea as well as puffiness around the eyes, especially in the morning. 
(National Kidney Foundation, 2010). The clinical presentation of CKD is generally 
non-specific but presentation trends have been seen with various types of kidney 
disorders that have resulted in the loss of kidney function. Diabetic kidney 
damage and glomerular diseases, namely proliferative glomerulonephritis and 
non-inflammatory diseases present with asymptomatic urinalysis abnormalities 
such as proteinuria, hematuria, casts and pyuria; whereas vascular diseases 
manifest as high blood pressure due to the urine abnormalities. Likewise, 
tubulointerstitial and cystic diseases have asymptomatic urinalysis abnormalities 
but include urinary tract symptoms such as dysuria, incontinence, flank pain and 
an increase in urine frequency and urgency (Levey et al, 2003).  
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1.2.3 Diagnosis of CKD 
 
Chronic kidney disease is often silent, preventing clinical presentation from being 
used for early diagnosis. It is often detected by chance, when routine blood and 
urine tests are run in search of another underlying health problem. Increased 
urea and creatinine levels in the blood, elevated blood pressure as well as 
proteinuria are the common abnormalities that are found and result in further 
testing. 
 
The methods for the analysis of the urea and creatinine levels, in both blood and 
urine, differ between laboratories, depending on the available resources. High 
performance liquid chromatography is considered the gold standard of creatinine 
determination due to its high specificity (Bishop, Fody and Schueff, 2005). This is 
a highly specialized test but is expensive both to purchase, set up and to run. 
Most laboratories use the kinetic-Jaffe reaction, which is inexpensive, rapid and 
easy to perform. In rural areas where laboratories are basic or non-existent, this 
kinetic-Jaffe reaction is done directly on a sample aliquot and the change in 
absorbance determined using spectrophotometry (Bishop, Fody and Scheuff, 
2005). This absorbance result is used to calculate the creatinine level. The typical 
human reference ranges for serum creatinine are as follows: 45-90 μmol/l for 
women and 60-110 μmol/L for men (Bishop, Fody and Scheuff, 2005). If filtering 
in the kidney is deficient, creatinine blood levels rise. A rise in blood creatinine 
level is observed only with marked damage to functioning nephrons rather than 
an indication of early-stage kidney disease. Low creatinine can also be a sign of 
certain diseases which cause decreased muscle mass, such as myasthenia 
gravis and muscular dystrophy (Marks and Mesko, 2002). These patients present 
with weakness, muscle wasting, and other symptoms; in addition to the abnormal 
blood levels. However these levels may not always be associated with disease 
states, with vegetarians showing lower creatinine levels due to the non-existence 
or decrease in protein intake and elderly people also having a lower creatinine 
level due to the decrease of muscle mass with age. A blood creatinine level of 
110 μmol/l can indicate significant renal disease in an elderly female while 150 
μmol/l is a normal range for a male body builder (Mandal, 2004). 
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The analysis of urea in blood or urine samples uses an enzymatic reaction, 
where urea is hydrolyzed and the ammonium ions that are produced are 
measured by the electrode of the analyzer (Bishop, Fody and Scheuff, 2005). As 
with creatinine, this method may be altered in rural areas and the ammonium 
from the reaction can be measured by the color change with a pH indicator. The 
gold standard for urea analysis is an enzymatic method involving both urease 
and L-glutamate dehydrogenase (GLDH) (Bishop, Fody and Scheuff, 2005). 
Urine is analyzed further with the use of dipsticks and microscopy analysis. 
Depending on the type of dipstick used, urine can be tested for the following: pH, 
protein, hemoglobin, glucose, ketones, specific gravity, urobilinogen and 
leukocyte esterases (Provan, 2010). The coincidental detection of proteins in a 
urine sample using the dipstick method provides important information as 
persistent proteinuria, specifically albuminuria, is a principal marker of kidney 
damage. Unfortunately, results obtained from a dipstick can be fairly unreliable 
as they are affected by the dilution of the urine and the specificity of the reaction 
(Levey et al, 2003). A positive protein result should be confirmed or investigated 
further with urine albumin determination. The urinary albumin excretion (UAE) is 
considered the gold standard for determining albumin levels in urine samples but 
is inconvenient and sometimes unavailable, as it requires a 24 hour urine 
sample. For this reason, the albumin:creatinine ratio (ACR) is recommended 
(Bishop, Fody and Scheuff, 2005). As renal function declines due to the loss of 
nephrons in the kidney, the glomerular capillary permeability increases. This 
allows small volumes of albumin to pass into the urine. These albumin levels are 
detected in the laboratory setting using albumin-specific immunoassays. The 
term microalbuminuria is used when describing low levels of albumin in the urine 
(Bishop, Fody and Scheuff, 2005). An ACR of less than 30 mg/mmol is 
considered normal in a healthy individual (National institute for health and clinical 
excellence, 2008). A result of >30 mg/mmol should be repeated with an early 
morning urine sample to confirm the presence of proteinuria. An initial result of 
greater than 70 mg/mmol, need not be repeated. In diabetic patients, 
microalbuminuria is clinically significant with a reference range of > 2.5 mg/mmol 
in men and > 3.5 mg/mmol in women. 
Stellenbosch University  http://scholar.sun.ac.za
 7 
 
 
 
Renal function is determined by the clearance of a specific substance from the 
body via the kidneys. This assesses the glomerular filtration rate (GFR) and is 
accurately measured by the renal clearance of inulin, the gold standard for the 
determination of renal function (Khurana, 2008).  Inulin is a dye that does not 
exist naturally in the body and is therefore freely filtered by the glomeruli, neither 
reabsorbed nor secreted in the nephron or metabolized in the body. Once a 
constant level of plasma inulin concentration is established, the GFR may be 
calculated using the following variable, where V is the urine flow rate in ml/min, 
and the urine and plasma inulin concentrations are measured in mg/ml (Khurana, 
2008): 
 
 GFR = UInulin x V 
          Pinulin 
 
Due to the invasive and expensive nature of the inulin clearance test, the 
clearance of creatinine is a more routinely used method for the determination of 
renal function and GFR calculation (Khurana, 2008). Creatinine has a fairly 
constant plasma concentration, is fully filtered by the glomeruli and is only 
secreted marginally in the tubules within the nephron. The samples required are 
a urine sample collected for a full 24 hour period and a random serum creatinine 
sample. A normalization factor is used to correct for body surface area and the 
formula becomes (Daniel, 2008): 
 
24 hour creatinine clearance (ml/min) = U x V    X    1.73 
                   P                A 
U = Urine creatinine concentration (mg/dl) 
V = Urine volume excreted in 24 hours (ml) 
P = Serum creatinine concentration (mg/dl) 
A = The patient’s body surface area (m2) 
(Perry, 2008) 
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A limitation of this test is the collection of a 24 hour urine sample. This can be 
challenging for patients and as a result it is generally not accurately collected 
(Puri, 2005). An equation that provided an estimate was proposed to replace the 
24-hour creatinine clearance using easily obtainable serum biochemistry, and as 
an easier method to determine renal function. This calculated the estimated GFR 
(eGFR), with GFR defined as the volume of fluid that is filtered by the glomerulus 
per minute (Levey et al, 2003). This equation became the preferred method of 
renal function estimation (Daniel, 2008). It does not require a urine sample and is 
corrected for age and weight, allowing an easier determination of GFR through 
calculation. 
 
Creatinine clearance (ml/min) = (140 - age) x weight x 0.85 (if female) 
                       72 x serum creatinine 
 
The ‘Modification of Diet in Renal Disease (MDRD)’ study equation is the most 
recent, commonly used formula for the estimation of GFR. The initial equation 
included serum albumin and urea nitrogen, however these were later dropped. 
The ethnicity factor usually used in the MDRD formula has been proven to be 
irrelevant in the black population of South Africa (Van Deventer et al, 2008). The 
result of this calculation is used for grading, treatment and dosing of renally 
excreted medication (Snyder and Pendergraph, 2005; Perry, 2008). 
 
GFR (mL/min/1.73m²)  = 175 x (Standardized serum creatinine)-1.154 x 
(Age)-0.203 x (0.742 if female)  
(Stevens & Levey, 2009)  
 
Both formulas used to estimate GFR were developed based predominantly on 
young, Caucasian patients (Daniel, 2008). However, these are not the individuals 
that are most at-risk for the development of CKD. The first at-risk group is the 
elderly. As the body ages, there is a natural loss of glomeruli due to a decline in 
the number of nephrons, glomerular capillary atrophy and overall kidney mass 
decline. Metabolic waste, specifically creatinine, is not excreted fully and the 
concentration builds up in the serum. This makes both the Cockcroft-Gault and 
the MDRD formulae somewhat inaccurate for estimating the GFR as the natural 
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decline in creatinine excretion by the kidneys is not accounted for. Many studies 
(Botev et al, 2009; Gouin-Thibault et al, 2007) have compared the use of both 
formulas, and observed that the Cockcroft-Gault formula underestimates the 
GFR slightly as it underestimates the creatinine clearance. This formula, 
therefore, is more applicable and accurate in elderly people for the estimation of 
GFR where creatinine excretion is less pronounced (Daniel, 2008). Other clinical 
situations where the eGFR may be unreliable or misleading include extremes in 
body size, high intake of dietary protein, vegetarian diets, or creatine 
supplements, severe liver disease, diseases of skeletal muscle, amputees or 
paraplegics due to the disparity in creatinine levels (Johnson et al, 2009). 
 
In 2009, Levey and co-workers developed another equation, the Chronic Kidney 
Disease – Epidemiology Collaboration (CKD-EPI) equation, based on serum 
creatinine levels that would be as accurate as the MDRD equation at a GFR of 
less than 60mL/min/1.73m² but more accurate at a higher GFR. Like the MDRD 
equation, the CKD-EPI includes race, age and sex and takes serum creatinine 
into account. This study showed that the CKD-EPI is more accurate than the 
widely used MDRD equation as it has a lower bias, preventing over-estimation of 
the GFR (Levey et al, 2009). The few studies that have been carried out since 
2009 (Michels et al, 2010; Madero and Samack, 2011) are all in agreement with 
the accuracy of the CKD-EPI equation. 
 
CKD-EPI equation: 
 
eGFR = 141 x minimum(Serum Creatinine/k,1)a x maximum(Serum 
Creatinine/k,1)-1.209 x 0.993age x [1.018 if female] x [1.159 if black]  
 
k = 0.7 for females and 0.9 for males 
a = -0.329 for females and -0.411 for males 
 
Kidney damage may be detected by other markers, including abnormalities in 
urine sediment such as casts and epithelial cells, renal tubular acidosis in blood 
and urine chemistry measurements; and abnormal findings on imaging studies 
including polycystic kidneys, hydronephrosis and small kidneys (Levey et al, 
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2005; Levey et al, 2003). Cystatin C is a more recently discovered marker of 
renal function (Hojs et al, 2006).  It is an endogenous, low molecular weight 
protein that is produced by all nucleated cells, and levels in the blood are not 
affected by age, gender, race or lean muscle mass. This protein is filtered by the 
glomeruli and reabsorbed and catabolized by the tubular epithelial cells, with only 
small amounts excreted in the urine. Since Cystatin C is not produced by the 
muscle, the problem of low creatinine in elderly patients due to low muscle mass 
or high creatinine levels due to high muscle mass is eliminated. Cystatin C is 
however affected by inflammation and immunotherapy (Daniel, 2008). In a study 
done by Stevens et al in 2008, the weak association between Cystatin C and 
age, sex and race was confirmed. Cystatin C alone was found to be more 
accurate in estimating the GFR than serum creatinine alone, but was slightly 
erroneous when compared to serum creatinine adjusted for age, sex and race. 
However, the main relevant outcome of the study was that an equation that used 
adjusted serum creatinine from the CKD-EPI equation, as discussed previously, 
as well as Cystatin C was the most accurate measure of the true GFR (Stevens 
et al, 2008). The CKD-EPI cystatin and creatinine equation adjusted for age, sex 
and race was defined as follows: 
 
eGFR:  177.6 x SCr-0.65 x CysC-0.57 x age-0.20 x 0.80 (if female) x 1.11 (if 
African American) 
 
Imaging studies are done once CKD has been diagnosed and helps with its 
prognosis by documenting the size of the kidneys, with a normal size indicating 
CKD that is amenable to treatment and smaller kidneys indicative of more 
irreversible damage. Imaging studies are also useful in identifying the cause of 
the kidney disease (Snyder and Pendergraph, 2005). When the cause cannot be 
determined using the patient’s history, medical conditions, laboratory results and 
imaging studies, a biopsy is suggested. This yields a definitive diagnosis but 
involves a risk. Kidney damage cannot be seen with the naked eye, and patients 
will only be diagnosed once symptoms are visible, when the glomerular filtration 
rate is already severely decreased. Target screening is therefore very important. 
With a known genetic variation in a specific race, this target screening will be 
made more specific. 
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1.2.4 Classification of CKD 
 
The results of many studies provide a strong foundation for using the GFR for 
classification purposes. The GFR is estimated using specific equations and 
based on a level less than 90 ml/min/1.73m2, as discussed in 1.2.3. The results 
are used to determine staging and treatment information for CKD, creating a 
standard for physicians and nephrologists worldwide by KDIGO in 2002 (Table 
1.1) (Levey et al, 2003). Many issues have been raised about stages 3, 4 and 5 
being defined solely on eGFR with no requirement of kidney damage or 
adjustment for age and gender (Glassock and Winearls, 2008). The KDIGO 
acknowledged the challenge against the 2002 CKD definition, a point that was 
already raised in 2004. Their response was to conduct a worldwide survey with 
nephrologists with the major concerns being documented and seriously 
discussed in 2008. Many suggestions of amendment were put forward but as of 
yet, no studies have been done to compare how they would perform against the 
2002 KDIGO system.  No common solution has been reached so far but it is 
likely to be revised in the near future (Hallan and Orth, 2010).  
 
Table 1.1: Classification of Chronic Kidney Disease. Taken from (Levey et al, 
2003; Levey et al, 2005; Hogg et al, 2003) 
 
STAGES DESCRIPTION 
eGFR 
(ml/min/1.73m²) 
ACTION 
- 
 
At increased risk 
 
≥ 90 with CKD risk 
factors 
Screening, CKD risk 
reduction 
1 
Kidney damage 
with normal or 
increased GFR 
≥ 90 
Treat comorbid 
conditions, reduce 
cardiovascular disease 
risk, slow the 
progression 
2 
Kidney damage 
with mild decrease 
in GFR 
60-89 Estimate progression 
3 
Moderately 
decreased GFR 
30-59 
Evaluate and treat 
complications 
4 
Severely decreased 
GFR 
15-29 
Prepare for kidney 
replacement therapy 
5 
Kidney failure (End 
stage renal 
disease) 
<15 Kidney replacement 
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1.2.5  Complications associated with CKD 
 
The major complications of chronic kidney disease include progression to kidney 
failure, cardiovascular disease, hypertension, anemia, malnutrition, bone 
diseases, neuropathy, gastrointestinal symptoms, electrolyte abnormalities, 
disordered calcium, phosphorous metabolism, immune dysfunction, decreased 
quality of life and premature death (Levey et al, 2005; Levey et al, 2003; Snyder 
and Pendergraph, 2005).  
 
1.2.6 Treatment of CKD 
 
As with most diseases, starting treatment at the earliest stage of CKD allows for 
the best possible outcome. The diagnosis of CKD, along with its stage or 
severity, complications or risk factors as well as comorbid conditions first need to 
be determined. This will allow for early intervention, with proper and possibly 
personalized treatment or therapy, based on lifestyle and specific genetic risk 
factors present in affected individuals. Identification of risk factors and availability 
of proper treatment and disease management strategies may postpone the loss 
of kidney function and prevent the development of accompanying cardiovascular 
disease (CVD) (reviewed by He and Whelton, 1999). Currently, affected 
individuals who have progressed to ESRD undergo dialysis, which is costly; or 
transplantation, which depends on the availability of compatible donors (Hogg et 
al, 2003).  
 
Table 1.1 details actions to be taken at specific CKD stages. Treatment of any 
comorbid conditions, interventions to slow progression of kidney disease, in 
addition to reducing the risk of cardiovascular disease, should all be initiated 
during stages 1 and 2. This stage of treatment is vital in increasing the length of 
time before ESRD. During stage 3, any complications that arise should be 
evaluated and treated. The prevalence of complications increases with a 
decreasing GFR of below 60ml/min/1.73m². Preparation for kidney replacement 
therapy should be done in stage 4, with preparation for dialysis and kidney 
transplantation beginning when the GFR drops below 15ml/min/1.73m², stage 5 
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(Levey et al, 2003; Hogg et al, 2003). Three interventions have been proven to 
slow the progression of CKD; the control of blood pressure, glucose level control 
in diabetic patients and the reduction of proteinuria with angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers (de Jong et al, 2008).  
 
1.3  EPIDEMIOLOGY OF CKD 
 
Chronic kidney disease is currently the 12th highest cause of death and 17th 
highest cause of disability worldwide (Nugenta et al, 2011). Factors contributing 
to the increase in the global prevalence of CKD include greater referral and 
acceptance due to a greater awareness in developed countries, and the rapid 
increase in the prevalence of diabetes and hypertension, which are both 
significant risk factors in CKD (Ronco, Brendolan and Levin, 2005). It is expected 
that the number of individuals with hypertension will increase from 972 million to 
1.56 billion people by 2025 and the diabetes incidence from 171 million in 2000 
to 366 million by 2030, of which 298 million of these will be in developing 
countries (Nugenta et al, 2011). Worldwide, more than a million patients are 
undergoing ESRD therapy, but the true prevalence of CKD is lacking (Molony 
and Craig, 2008). In developed countries, the ESRD patients taking treatment are 
monitored, allowing for a fairly accurate burden of ESRD to be determined, 
however the number of patients with ESRD is just a small proportion of the entire 
burden of CKD (Goldsmith, Tayawardene and Ackland, 2007). The number of 
patients with stage 1 to 4 CKD is not as easy to determine as statistics only show 
those being treated, not those who do annual follow-ups for basic comorbid 
condition control or treatment. Information from developing countries in Asia, 
Africa and South America is scarce due to the lack of renal registries and 
databases, but it can be estimated that the CKD prevalence and burden will be 
significantly higher than developed countries. There are multiple potential 
explanations for the variability between developed and developing countries; 
however the most apparent factors include access to health care, the 
effectiveness of detection and treatment of kidney disease and population 
specific risk factors (Molony and Craig, 2008).  
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This rapid rise of diabetes and hypertension, as well as obesity, will result in an 
even greater and more profound burden that developing countries are not 
equipped to handle. With a 10 - 16% prevalence of diabetes in South Africa and 
1 in 5 adult South Africans with hypertension, CKD is a scary reality in this 
country (Katz, 2005; Southern African Hypertension Society, 2011). At the same 
time, many developing countries are experiencing significantly high rates of 
infectious diseases which initiate and increase progression of CKD such as 
schistosomiasis, human immunodeficiency virus (HIV), tuberculosis (TB), 
amyloidosis and hepatitis B and C (White, 2008). Poverty and socio-economic 
status are highly correlated with the common risk factors of CKD, including 
hypertension, diabetes, obesity, smoking and dyslipidaemia, making low to 
middle income countries, such as South Africa, particularly vulnerable to the CKD 
burden (Nugenta et al, 2011). 
 
A review done in Cape Town (South Africa) of renal biopsy results over a 10 year 
period showed that primary or secondary glomerulonephritis was the main cause 
of CKD. 53.7% of the study population consisted of patients of the mixed 
ancestry ethnic group (Okpechi et al, 2010). Glomerulonephritis is caused, by 
among others, autoimmune diseases such as systemic lupus erythematosus 
(SLE), HIV, viral hepatitis, drug abuse and infections such as TB and malaria. 
HIVAN increased from 6.6% in 2000 to 25.7% in 2009. In 2007, South Africa had 
17% of the global burden of HIV and one of the world’s worst TB epidemics 
(Karin et al, 2009). These statistics, coupled with the diabetes and hypertensive 
prevalence, make CKD a grave burden in South Africa.  
 
Chronic kidney disease has not been given enough attention globally, largely due 
to the global health community’s focus on infectious diseases, importantly HIV, 
as well as the lack of awareness about CKD. There is thus a critical need for 
funding in developing countries in order to implement more comprehensive, cost-
effective, and preventative interventions against CKD. Providing care for patients 
who require dialysis or transplantation is a major and growing healthcare problem 
in both developed and developing nations in terms of cost, premature mortality 
and economic impact (Goldsmith, Tayawardene and Ackland, 2007).  
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1.4 MARKERS FOR CKD PROGRESSION 
 
Markers for CKD initiation and progression are important in the prediction of 
patients at risk for progression of CKD and its consequences. The identification 
of reliable and accurate markers will allow for a better understanding of the 
pathogenesis and progression of CKD. Proteinuria, along with other kidney 
abnormalities, such as urine sediment and imaging irregularities, has already 
been identified as kidney damage markers. However, new markers are needed to 
detect kidney damage prior to the reduction of the GFR. Novel low molecular 
weight proteins are being increasingly studied, with many showing great promise.  
 
1.4.1 Asymmetric Dimethylarginine (ADMA): The reduced availability of nitric 
oxide (NO) was hypothesized to play a role in the progression of kidney disease 
(Fliser et al, 2005). Nitric Oxide is a vasodilator that is found in the endothelium of 
the kidney and is important in the regulation of blood flow. Decreased levels of 
NO results in decreased renal plasma flow, increased blood pressure, and 
increased renovascular resistance (reviewed by Kronenberg et al, 2009). ADMA 
is an endogenous inhibitor of NO synthase that has a long duration of action, with 
the kidney being the main site of ADMA excretion. The role of increased plasma -
-ADMA has been studied in diabetes, pre-eclampsia, strokes and vascular and 
coronary heart diseases (Vallance, 2001; Cooke, 2004; Achan et al, 2003). 
Individuals with ESRD undergoing hemodialysis have high plasma ADMA levels 
and this is a strong and independent predictor of overall mortality and 
cardiovascular outcome (Zoccali et al, 2001). Though data showing elevated 
ADMA levels in CKD patients (Cooke, 2004) and experimental data 
demonstrating the association between increased ADMA levels and the 
progression of CKD had been published, a study done by Fliser et al (2005) was 
the first to demonstrate the role of ADMA and CKD progression in humans, 
namely non-diabetic CKD patients. Remarkably, plasma ADMA was the only 
independent predictor of progression apart from serum creatinine. A subsequent 
study (Ravani et al, 2005) was done on CKD patients with either diabetes or 
cardiovascular complications, and a 20% increased risk of mortality was 
identified for every 0.1 μmol/L increase of plasma ADMA, independent of 
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hemoglobin, GFR and proteinuria. To further prove the association between 
increased ADMA and DN, Hanai et al (2009) did a cohort study on type 2 diabetic 
patients of Japanese descent. They demonstrated that higher levels of ADMA 
was associated with faster progression of nephropathy in diabetic individuals, 
based on increased albuminuria and decreased eGFR. ADMA shows immense 
promise as a CKD marker but has as yet, not been submitted to the Food and 
Drug Administration (FDA) and European Medicines Agency (EMEA) for 
recognition as a biomarker associated with nephrotoxicity (reviewed by Fassett et 
al, 2011).  
 
1.4.2 Fibroblast growth factor 23 (FGF-23): FGF-23 has been identified as a 
phosphatonin, decreasing phosphate reabsorption in the kidney, and is 
associated with increased phosphate excretion and decreased plasma 
phosphate concentrations (reviewed by Bernt, Schiavi and Kumar, 2005). A 
disturbed calcium-phosphate metabolism and CKD progression have been linked 
(reviewed by Block et al, 2004), and increased levels of FGF-23 have been noted 
in CKD patients and those already in ESRD (Imanishi et al, 2004; Larsson et al, 
2003) However, the assays used in these studies detected both the intact FGF-
23 molecule and its COOH-terminal fragments. This made it difficult to assess 
whether there was a decrease in the degradation of full-length FGF-23 or if the 
FGF-23 fragments are biologically inactive. A study by Flisher et al (2007) 
examined the association of CKD progression with both intact FGF-23 as well as 
the c-terminal level. The findings showed a significantly faster CKD progression 
time when levels of c-terminal FGF-23 were above the optimal cut-off level of 
104rU/mol (46.9 months) when compared to patients who had intact FGF-23 
level above the median concentration of 35pg/ml (54.6 months). Additionally, 
CKD patients with c-terminal levels within the normal limits had a longer 
progression time (72.5 months) than patients with intact FGF-23 levels below the 
threshold (69.8 months). After adjustment for GFR, the CKD progression 
estimates by FGF-23 were still significant, suggesting that FGF-23 is an 
independent prediction marker and not simply a surrogate marker of GFR. 
Finally, should the FGF-23 c-terminal increase to 250rU/ml, the risk for CKD 
progression increases to 35% (p<0.001), adjusted for age, sex, GFR and 
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proteinuria (as reviewed by Kronenberg et al, 2009). The c-terminal of FGF-23 is 
easier to measure than the intact FGF-23 molecule, and given this, subsequent 
studies have focused on the c-terminal levels in CKD progression association 
studies.   
 
1.4.3 Vitamin D: Vitamin D deficiency has long been linked to traditional 
cardiovascular risk factors such as hypertension, insulin resistance, diabetes, 
and dyslipidemia (Forman et al, 2007; Pittas et al, 2006); and is also associated 
with albuminuria and a higher prevalence of mortality in the Third National Health 
and Nutrition Examination Survey (NHANES) cohort (Mehrotra, Kermah and 
Salusky, 2009; De Boer et al, 2007).  The adequacy of body vitamin D stores is 
best assessed by the measurement of the serum level of 25-hydroxyvitamin D 
(25(OH)D) (reviewed by Kandula et al, 2011). However, 25(OH)D needs to 
undergo 1-α hydroxylation for it to be converted into the active form, 1,25-
dihydroxyvitamin D (1,25(OH)2D). The kidneys are the primary site for 1-α 
hydroxylation of vitamin D, due to the presence of 1α hydroxylase in the proximal 
and distal tubules, as well as the ascending Loop of Henlé (Zehnder et al, 1999). 
The renal synthesis of 1,25(OH)2D is tightly regulated by complex interactions 
between the parathyroid hormone (PTH), calcium and phosphate. An association 
between mortality and vitamin D deficiency has been shown in both dialysis and 
non-dialysis dependent CKD (Wolf, 2008; Mehrotra, Kermah and Salusky, 2009). 
Intervention studies have also been done using an active Vitamin D analog, 
showing a reduction in proteinuria among CKD patients (Fishbane et al, 2009; 
Agarwal, 2009). A definitive study done by Ravani et al (2009), revealed that for a 
10ng/ml increase in 25(OH)D levels, the associated CKD progression had a 40% 
decrease in the hazard ratio. This study proved that 25(OH)D is an independent 
inverse predictor of disease progression and death in patients with stage 2-5 
CKD.    
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 18 
 
 
1.4.4 Adiponectin: Adiponectin is a cytokine specific to, and produced in the 
adipocytes. It has a central role in glucose and lipid metabolism as an insulin 
sensitizer, an anti-inflammatory, anti-atherosclerotic and vasculo-protective 
cytokine (reviewed by Kronenberg et al, 2009). Adiponectin is abundant in 
plasma but a large number of studies have shown an association between low 
adiponectin levels and negative outcomes, such as obesity and type 2 diabetes 
mellitus (Arita et al, 1999; Hotta et al, 2001), in addition to coronary artery 
disease (Kumada et al, 2003; Pishon et al, 2004; Schulze et al, 2005). However, 
adiponectin is elevated in patients with kidney impairment, with kidney function 
being an important determinant of circulating levels of cytokines (Becker et al, 
2005). When kidney function decreases, the proposed mechanisms for 
adiponectin level disturbances are changes in the ligand or receptor reactivity as 
shown for other hormone or receptor systems in renal failure, reduced 
adiponectin clearance by the kidney, or a counter-regulatory response to 
metabolic derangements in renal failure (reviewed by Shen, Peake and Kelly, 
2005; Isobe et al, 2005; Zoccali et al, 2003). Adiponectin levels are also 
increased in type 1 diabetes patients and DN (Imagawa et al, 2002; Saraheimo et 
al, 2005). A study done by Kollerits et al (2007), found that increased adiponectin 
levels were an independent predictor of CKD progression, however only in men. 
Conflicting results on the cause and effect of high adiponectin levels in CKD 
patients are rife, with some studies suggesting that the high levels are a marker 
of poor prognosis (Menon et al, 2006), and others suggesting that the high levels 
play a protective role by reducing albuminuria through a direct effect on podocyte 
function and modulation of inflammation and oxidative stress (Sharma et al, 
2008; Komura et al, 2010). Supportive of this protective view are studies showing 
that high adiponectin levels have been associated with a better prognosis in 
ESRD and CVD patients, with a lower risk for cardiovascular events in ESRD 
patients (Zoccali et al, 2002). Conversely, Saraheimo et al (2008) demonstrated 
that patients with normoalbuminuria or microalbuminuria had no differences in 
the baseline adiponectin concentrations between those who had CKD 
progression or those with no CKD progression.  However, in the 
macroalbuminuria group, progressors had significantly higher serum adiponectin 
concentrations compared with non-progressors. A review by Fassett et al (2011), 
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is against the view that adiponectin cannot be considered as a biomarker for 
early detection of CKD progression due to the association between albuminuria 
and adiponection with CKD progression. Because of its association with other 
lifestyle diseases, adiponectin cannot be disregarded and further studies should 
be done to determine the effect of elevated adiponectin levels in CKD.  
 
1.4.5 Apolipoprotein A-IV (Apo A-IV): Apolipoprotein A-IV is a plasma protein 
synthesized in the intestines and excreted into the circulation on chylomicron 
particles (Weinberg and Spector, 1985). Apo A-IV activates lecithin-cholesterol 
acyltransferase (LCAT) enhancing the formation of small high dense lipoprotein 
(HDL) particles, modulates the activation of lipoprotein lipase (LPL), has anti-
oxidant and anti-atherogenic properties, stimulates cholesterol efflux from 
peripheral cells, as well as having involvement in several steps of the reverse 
cholesterol transport pathway. Although the liver is the main site of degradation 
of apo A-IV, the kidney contributes significantly (Haiman et al, 2005). The initial 
localization of apo A-IV in the kidney identified it in the brush border cells of the 
proximal tubules and in the granules of the epithelial cells in the proximal tubule, 
where the apo A-IV was degraded within the lysosomes. Localization of apo A-IV 
was also done in the distal tubules, concluding that apo A-IV is not filtered by the 
glomerulus but rather reaches the tubules to be absorbed. There has been little 
doubt that CKD is associated with abnormalities in lipoprotein metabolism, 
however a study done by Boes et al (2006) was the first to investigate the 
association between the apo A-IV concentration and the progression of CKD. 
The findings showed that plasma apo A-IV concentrations above the baseline 
level was one of the best predictors for the progression of kidney disease, apart 
from baseline GRF. This association was independent of other lipoproteins, 
ADMA, proteinuria, blood pressure and inflammatory status. Additionally, an 
increase of apo A-IV to 10mg/dL results in a 60% increase in risk of CKD 
progression. These findings, along with the reports on increased apo A-IV 
concentration in hemodialysis patients (Seishima and Muyo, 1987; Dieplinger et 
al, 1992; Kronenberg et al, 1995) and the demonstration that patients with kidney 
disease have significantly increased apo A-IV concentrations even when the 
GFR is still within normal range (Kronenberg et al, 2002), allows for the 
conclusion that apo A-IV is an early marker for renal insufficiency. This is 
Stellenbosch University  http://scholar.sun.ac.za
 20 
 
 
supported by the recent findings of apo A-IV immunoreactivity in kidney tubular 
cells, suggesting a direct role of the human kidney in apo A-IV metabolism  
 
1.4.6 Natriuretic peptides: A natriuretic peptide refers to proteins that induce the 
loss of sodium in the urine, and includes the atrial natriuretic peptide (ANP) and 
brain natriuretic peptide (BNP) (Shils et al, 2005). ANP is a powerful vasodilator, 
involved in maintaining cardiovascular and renal homeostasis, and is secreted by 
the atrial monocytes of the heart. A study done by Dieplinger et al (2009) showed 
by using multiple Cox-proportional hazard regression analyses, that an elevated 
plasma concentration of ANP was strongly predictive of the progression of CKD 
after adjustments for age, gender, GFR, proteinuria and pro-B-type natriuretic 
peptide, suggesting it to be a useful new marker. BNP is secreted by the 
ventricles of the heart, with similar physiological actions as ANP (Shils et al, 
2005). The N-terminal fragment (NT-proBNP) is an inactive molecule and results 
from the cleavage of the prohormone pro-BNP, and is solely reliable on renal 
excretion. Both the BNP and NT-proBNP levels increase as the GFR declines 
(Austin et al, 2006). The increasing ratio of NT-proBNP/BNP with decreasing 
GFR was seen in the same study, indicating that NT-proBNP is influenced to a 
greater degree by renal function. These results were consistent with other studies 
(DeFilippi et al, 2005; Richards et al, 2006). The independent influence of renal 
function on BNP was taken into account due to the presence of heart disease 
among participants, and the cases were separated into CKD with evidence of 
heart disease, and CKD without evidence of heart disease. As found by Takami 
et al (2004),  without fluid overload, distinctive of heart disease, there was no 
elevation of BNP even with the presence of severe renal dysfunction. The BNP 
and NT-proBNP levels were all normal for the group without heart disease. BNP 
and NT-proBNP was then deemed an indicator for mortality due to cardiac 
complications or cardiac hospitalization in patients with renal disease, and a 
marker for early detection of cardiac complications arising from CKD. The precise 
influence of CKD on BNP and NT-proBNP levels continues to be debated and 
studies show plasma BNP dependence on the GFR among patients with and 
without heart failure. Additional prospective studies will be required to validate 
and better define the relationship between BNP, NT-proBNP and CKD 
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progression, independently of myocardial dysfunctions. Nevertheless, should 
these validations never arise, the screening of a sensitive marker for cardiac 
complications of CKD is still of importance.  
 
1.4.7 Neutrophil gelatinase-associated lipocalin (NGAL): Neutrophil 
gelatinase-associated lipocalin is an iron-carrying protein that is expressed and 
released in large amounts from the tubular epithelium of the distal nephron 
following acute kidney injury (AKI), ischemia or toxicity (Bolignano et al, 2009). 
Increased NGAL levels in the urine have been associated with an increased CKD 
progression to ESRD, with the levels increasing as the CKD increases in severity 
(reviewed by Fassett et al, 2011). Serum and urine NGAL levels are increased in 
diabetic patients, suggesting a role in the development of DN. Additionally; 
significant correlations have been found between serum and urine NGAL levels 
and eGFR, and urinary NGAL levels and the degree of proteinuria. There is now 
strong evidence that increased urinary and serum NGAL reflect damage across a 
spectrum of kidney diseases, as well as AKI, and may predict progression of 
CKD.  
 
1.4.8 Kidney injury molecule-1 (KIM-1): Kidney injury molecule-1 is a 
transmembrane tubular protein with uncertain function, however it is believed to 
play a role in tubulo-interstitial damage (Ichimura et al, 1998). This homologue is 
predominant in the kidney, predominantly expressed in tubular cells, and 
contains a highly conserved tyrosine kinase phosphorylation motif at position 350 
(reviewed by Waanders et al, 2010). KIM-1 is not detectable in the urine from 
individuals with normally functioning kidneys. Elevated urine KIM-1 levels have 
been described in AKI and CKD. A study done by Van Timmeren et al (2007) 
found significantly higher KIM-1 levels in patients with tubular necrosis as 
opposed to the still significant but substantially lower levels in various chronic 
renal diseases. Urinary KIM-1 levels in renal disease were associated with 
tubular KIM-1 and renal inflammation, but not to proteinuria. There was no 
relation found between urinary KIM-1 with glomerular damage and interstitial 
fibrosis. Urinary KIM-1 levels might therefore represent only the degree of 
ongoing tubular damage, and might be a promising biomarker for assessing the 
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progressive nature of renal disease. However, the almost complete absence of 
KIM-1 in healthy kidneys resulted in some studies concluding that KIM-1 plays a 
role in the renal regeneration process (Ichimura et al, 1998). This is yet to be 
determined and controversy exists as to whether KIM-1 is involved in actively 
regulating the inflammation process, or if the expression of KIM-1 is purely a 
response to kidney damage, does KIM-1 attempt to repair damage or is it part of 
a recovery process (reviewed by Waanders et al, 2010). Long term observational 
studies in large populations are required to assess urinary KIM-1 as a CKD 
biomarker. 
 
It is unlikely that one single marker will satisfy the need to predict CKD 
progression, morbidity and mortality. Chronic kidney disease is a complex 
disease with multiple pathophysiological processes involved. A panel of 
confirmed biomarkers would be the ideal conclusion, with a review of all the 
markers done together as they may have additive effects on CKD progression, 
morbidity and/or mortality. Large studies are required urgently for the more 
established markers and more intense investigation into the ‘newer’ biomarkers, 
such as pentraxin-3, urinary interleukin 8 and liver-type fatty acid binding protein. 
Several novel urinary markers show promise of non-invasive demonstration of 
kidney damage or prediction of disease progression. None appear to be ready at 
this time for widespread application in clinical practice.  
 
1.5 AETIOLOGY OF CKD 
 
1.5.1 Non-modifiable factors 
 
Non-modifiable factors refer to factors that cannot be changed or adjusted. These 
are termed susceptibility factors, increasing the risk for adverse outcomes of 
CKD. Susceptibility factors increase the vulnerability to kidney damage such as 
old age, gender, a family history of CKD, ethnicity, a low birth weight or small 
kidneys, as well as genetic variants proven to be associated with CKD or any of 
the known conditions causing CKD (Hogg et al, 2003) These genetic mutations 
will be discussed in further detail in 1.5.4.  
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1.5.1.1 Age: The NHANES is a group of studies that assess the health and 
nutritional status of the population in America. Due to the lack of CKD prevalence 
studies in South Africa, we have to rely on external statistics and extrapolate the 
results. According to the NHANES Annual Data Report, 85% of individuals with 
an eGFR of less than 60ml/min/1.73m2 are 60 years or older (Bethesda, 2011). 
This value confirms the increasing risk of CKD with age. A significant observation 
that must be noted is the natural aging of the kidney, with deterioration of both 
structural and physiological features (reviewed by Silva, 2005). The scarring of 
the glomerulus (glomerulosclerosis) starts from the age of 30, and by the age of 
70 the mesangium has increased by 12%. This is followed by the formation of a 
direct channel between the afferent and efferent arterioles. The arterioles show 
the deposition of hyaline and collagen fibers while the smaller arteries are 
thickened due to the proliferation of the elastic tissue. The renal tubules undergo 
atrophy and fibrosis (reviewed by Silva, 2005). These anatomical changes cause 
a decrease in the GFR as the plasma flow is affected. The diminished response 
to stimuli with the reduced sodium reabsorption and plasma concentrations of 
renin and aldosterone causes a greatly increased fractional excretion of sodium 
and overall urine sodium excretion. The ability to concentrate and dilute ones 
urine is also slowly lost along with decreased potassium secretion and urea 
absorption (Lindeman, Tobin and Shock, 1985). These changes can easily be 
mistaken for CKD and need to be investigated (these normal changes in healthy 
patients can be determined by a normal hemoglobin concentration, normal 
erythropoietin levels and a normal urinalysis result); as these natural changes 
can themselves initiate CKD or cause cardiovascular disease, which in turn leads 
to CKD (Musso and Oreopoulos, 2011). The monitoring of patients is important.   
 
1.5.1.2 Gender: Information on the gender differences in GFR and therefore 
CKD prevalence is conflicting. The Third NHANES noted prevalence of a GFR of 
less than 80ml/min/1.73m2 in 54% of men and 68% of women when using the 
MDRD formula and a 25% and 53% prevalence respectively using the Cockcroft-
Gault formula. When breaking down the prevalence by age group, men and 
women in the age group 30-59 years and 60-79 years, had prevalence’s of 
9%:17.5% and 45.2%:50.2% respectively. However, the most significant GFR 
difference between men and women is for those over the age of 80 with 45.8% of 
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men and only 32% of women falling in this category (Clase, Garg and Kiberd, 
2002). Other studies have confirmed the statement that women have a lower 
GFR than men (Rule et al, 2004). However, there are studies showing that it is 
the rate of progression of renal disease that differs between genders, rather than 
the initial prevalence in men and women, which is more rapid in men than in 
women (Silbiger and Neugarten, 1995). There are genetically determined 
differences between the sexes in renal structure and function as well as the 
influence of sex hormones, all of which will have a bearing on the susceptibility 
and progression of CKD (Sabolić et al, 2007). These observations are said to 
give women a gender-related advantage, which is lost after menopause as 
estrogen levels drop. Whether these differences favor males, females or neither 
is controversial and debatable. Latest KDOGI guidelines state that 18 studies 
have addressed the impact of gender on GFR.  Results suggest either an 
association of faster progression with males, association of faster progression 
with females or finally no association between either gender or progression. 
Though these results are indecisive, the impression is that progression is faster 
among men. Until conclusive findings are obtained through research, this 
decision is taken as the gold standard of guidelines (National Kidney Foundation, 
2006).  
 
1.5.1.3  Ethnicity: Racial risk studies conducted, initially in the United States of 
America and subsequently globally, have noted that racial minorities and 
indigenous populations are mostly at risk, specifically, African Americans, Native 
Americans, the Asian population and Aboriginal people (Mehrotra et al, 2008). 
According to the United States Renal Data System (USRDS) 2011 report, African 
Americans had the highest prevalence of CKD in America with 5284 patients per 
million followed by Native Americans with 2735 patients per million. This entirely 
overshadows the 1279 patients per million in the Caucasian American 
population. Due to this obvious increase in risk, MDRD, CKD-EPI and  CKD-EPI 
Cystatin C equations each have an African American factor included to equate 
for this increase in risk. Higher rates of modifiable metabolic-related disorders 
such as obesity, diabetes, and hypertension are becoming more predominant 
among indigenous populations (Mehrotra et al, 2008). This can be explained by 
the changing environment, adoption of a Western diet with less physical activity 
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and poor lifestyle factors associated with low socio-economic status. It is these 
environmental changes and socio-economic conditions that exert a great 
influence on the health and disease among the subpopulations (Nicholas et al, 
2005). The disproportionately high rate of CKD among the racial minorities 
worldwide, emphasizes the need to re-evaluate the identification, diagnosis and 
treatment of CKD in countries with diverse communities, such as South Africa. 
 
1.5.1.4 Low birth weight: Low birth weight has been identified as a risk factor 
not only for obesity, but for the development of CKD as well (Griffen, Kramer and 
Bidani, 2008). The relationship was first described by Dr Barker in the 1980’s, 
when he showed that the lower the weight of the baby at birth, the higher the risk 
of developing coronary heart disease in adulthood (Brenner, Garcia and 
Anderson, 1988). Further studies showed that the low birth weight was also 
associated with hypertension, stroke and type 2 diabetes, and was deemed the 
‘Fetal Origins Hypothesis’, and later the Barker’s Hypothesis. These 
manifestations were due to under nutrition during fetal life, leading to a low birth 
weight, which permanently changed the body’s structure, physiology and 
metabolism (Brenner, Garcia and Anderson, 1988). Barker’s hypothesis has 
been modified into the Brenner Hypothesis, which states that a congenital 
reduction in nephrons due to a low birth weight or intrauterine growth retardation 
results in a greater likelihood of the onset of adult hypertension and subsequent 
renal failure (Wadsworth et al, 1985). A low birth weight has been associated with 
a decreased number of nephrons, and should there be delayed fetal growth, 
even in a full-term pregnancy, there can be a decrease of up to 20% of the 
number of nephrons. This becomes evident in adulthood with the manifestation of 
hypertension and a decreasing GFR (Mañalich et al, 2000). The decreased 
number of nephrons (termed oligonephronia) results in an increased pressure on 
the remaining nephrons’ capillaries, contributing to glomerular damage.  This 
increases renal vulnerability and exacerbates the progression of renal disease 
(Reyes and Mañalich, 2005). Congenital, hereditary and acquired CKD has also 
been associated with children born prematurely, with a study in 2010 by Franke 
et al having statistics as high as 39.3%, 24.7% and 15.5%, respectively. These 
results suggest that children who are born prematurely and at a lower than 
normal birth weight are more predisposed to high-grade CKD. 
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1.5.1.5 Small kidney size: As with low birth weight, small kidneys have also 
been associated with a reduced number of nephrons (Franke et al, 2010). With a 
decrease in glomerular number and size, there is an unmistakable correlation 
with decrease in kidney weight. This results in glomerular hypertension in the few 
nephrons available, which, in turn, triggers a cycle of progressive loss of renal 
function (Nvengaard and Bendtsen, 1992).  
 
1.5.1.6 Family history of CKD: Family history of CKD can be mainly attributed 
to the genetic factors associated with CKD, which will be discussed later in this 
review (1.5.4). A study completed between 1995 and 2003 demonstrated a 23% 
incident of dialysis in patients with first or second degree relatives who had been 
diagnosed with ESRD, and far more are likely to have family members with silent 
proteinuria or CKD (Freedman et al, 2005). This percentage did not include 
cases of ESRD with Mendelian inheritance. This high prevalence could partially 
be explained by the presence of CKD susceptibility genetic factors and common 
lifestyle factors. 
 
1.5.2  Lifestyle factors 
 
Lifestyle factors contributing to CKD, also referred to as modifiable factors, 
describe causes of CKD that are controllable and can be prevented or avoided.  
The two main modifiable causes of chronic kidney disease are diabetes and high 
blood pressure, which are responsible for up to two-thirds of the cases of CKD 
(National Kidney Foundation, 2010). These medical conditions are referred to as 
initiation factors as they directly initiate kidney damage (Hogg et al, 2003). 
Additional modifiable factors include smoking, excess alcohol intake (Stengel et 
al, 2003), excessive sun exposure, pollutants such as toxic waste, diesel 
particles, and organic pollutants (Delfino et al, 2009; Orth and Hallan, 2008; Gee 
and Payne-Sturges, 2004).  
 
Type 1 diabetes is characterized by the autoimmune destruction of the insulin 
producing β-cells of the pancreas, whereas in type 2 diabetes, cells with insulin 
receptors are resistant to the action of insulin (Gillespie, 2006; Stumvoll, 
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Goldstein and van Haeften, 2005).  Current WHO diagnostic criteria for diabetes 
mellitus is a fasting plasma glucose ≥ 7.0 mmol/l or 2–h plasma glucose ≥ 11.1 
mmol/l (WHO, 2006). Between 20%-40% of patients with diabetes will ultimately 
develop DN (Dronavalli, Duka and Bakrus, 2008).   Initiation and progression of 
DN differs according to the type of diabetes present as well as the presence or 
absence of microalbuminuria. The presence of albuminuria increases the 
prevalence of initiation of DN to 80% (Dronavalli, Duka and Bakrus, 2008). There 
are many distinct stages of the development of DN. Initially, functional changes 
will occur in the nephron before any biochemistry results show a problem. This 
hyperperfusion and hyperfiltration is caused by the decrease in the resistance to 
blood flow in both afferent and efferent arterioles in the glomerulus (Dronavalli, 
Duka and Bakrus, 2008). This results in increased blood flow into the glomerulus, 
thereby increasing glomerular pressure.  Decreased resistant action has been 
attributed to many factors including prostaglandins, vascular endothelial growth 
factor A, repeated stretching and relaxation of the mesangial cells and 
transforming growth factor β (TGF-β). TGF-β is an extensively researched 
mediator in DN (Zihadeh, 2004). It is stimulated by, to mention a few, a high 
glucose concentration, products of the gylcation of proteins, oxidative stress, 
glucoseamine overproduction and high levels of angiotension II, endothelin and 
thromboxane. This cytokine promotes the synthesis of extracellular matrix and 
decreases the matrix degradation by inhibiting proteases. 
 
 Cytokines and growth factors are involved in the cascade leading to kidney 
damage by causing oxidative stress, abnormal glycosylation, lipid peroxidation, 
and the production of additional inflammatory elements (Dronavalli, Duka and 
Bakrus, 2008). Ultimately, albumin leakage from the glomerular capillaries 
ensues, accounting for the microalbuminuria.  Initial hemodynamic changes due 
to growth factors, cytokine and vasoactive system disturbances associated with 
diabetes are further exacerbated by the hyperglycemia. Hyperglycemia is 
associated with an increase in mesangial cell proliferation and hypertrophy, 
resulting in glomerular hypertrophy, mesangial expansion and glomerular 
basement membrane thickening (Dronavalli, Duka and Bakrus, 2008).  Mesangial 
expansion due to an increase in matrix production further stimulates TGF-β 
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secretion and reduces the capillary area for filtration, further decreasing the renal 
function (Ichnose, Kawasaki and Eguchi, 2007).  The development and outcomes 
of DN, as well as the decline in the rate of kidney function, occur via multiple 
mechanisms. It is greatly variable between patients and is influenced by 
additional factors including blood pressure, glycaemic control that may lead to 
metabolic and hemodynamic changes, as well as genetic predisposition.  
 
Hypertension is the second leading cause of ESRD and plays a predominant role 
in the progression of CKD (Bidani and Griffen, 2004). Systolic blood pressure of 
above 140 mmHg is considered hypertensive (WHO, 2004). Hypertensive 
nephrosclerosis (HN) is either benign or malignant, with the benign 
nephrosclerosis pattern showing non-specific hyaline arteriosclerotic lesions 
developing slowly over time with no obvious proteinuria and only severely 
compromised GFR in susceptible individuals; whereas malignant nephrosclerosis 
is characterized by severe hypertension and disruptive vascular and glomerular 
injury accompanied by fibrosis, necrosis, myointimal hyperplasia and thrombosis 
(Bidani and Griffen, 2004).  Arteries and arterioles are narrowed, resulting in 
glomerular ischemia. Blood pressure load can be controlled by maintaining the 
blood pressure within a certain limit, this is characteristic of benign 
nephrosclerosis.  Regulatory vasoconstriction of the afferent arteriole supplying 
blood to the glomerulus attempts to maintain a relatively constant renal blood 
flow, protecting against renal damage. Should blood pressure exceed the 
maintainable limits, malignant nephrosclerosis ensues, causing vascular injury 
(Bidani and Griffen, 2004). Hypertension is an initiation factor causing renal 
damage and is also a consequence of renal disease, contributing to the 
complexity of HN. When renal function is compromised due to other factors, the 
sodium-potassium pump within the kidney is disrupted, affecting the blood 
pressure regulation, resulting in secondary HN from primary renal disease. 
Conversely, malignant hypertension has been associated with renal damage, 
with increased blood pressure a strong predictor of a decline in renal function 
resulting in CKD (Fervenza, 2012). The difficulty in determining whether it was 
the renal damage or the hypertension which manifested first, leads to difficulty in 
CKD typing. HN may be diagnosed on a long-standing history of hypertension 
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and moderate proteinuria, without any evidence indicating an alternative 
diagnosis (Fervenza, 2012). However, regardless of the aetiology of the HN, 
once hypertension develops, a cycle of renal injury, nephrosclerosis, aggravation 
of hypertension and further renal damage ensues and main focus on prevention, 
early detection and proper control procedures is important. 
 
Susceptibility to hypertensive vascular injury with a reduced blood pressure load 
limit and lower threshold for damage is seen in already existent CKD, due to 
diabetes or other factors such as genetic susceptibility. Collectively, 
hyperinsulinemia in diabetes plays a role in hypertension initiation and 
aggravation by increasing platelet adhesion and aggregation, causing an 
imbalance between coagulation and fibrolytic activity and ultimately leading to a 
pro-coagulant state, endothelial dysfunction, lipoprotein abnormality, and 
vascular smooth muscle alteration (Acharya, 2001). This links the first major risk 
factor in CKD, diabetes, to the second, hypertension. Each condition promotes 
and aggravates the other, as one is uncontrolled, so the next is initiated or 
enhanced.  
 
Obesity is another chronic disease risk factor that plays a significant role in the 
initiation and progression of CKD (Schmitz et al, 1992; Wolf, 2003; Chagnac et 
al, 2003). There are many factors that contribute to the obesity epidemic and 
these include high intake of refined carbohydrates and fats, urbanization, 
sedentary lifestyle that results in reduced physical activity due to technological 
advances and the use of transportation (World Health Organization, 2006). 
Obesity is the main driving force for both the diabetes and hypertension 
epidemics (Coldits et al, 1990; Ascherio et al, 1998; Field et al, 2001). Adipose 
tissue secretes many hormones that regulate insulin sensitivity such as 
cytokines, leptin, resistin and adiponectin. (Silha et al, 2003). Adiponectin is the 
main focus of type 2 diabetes-related insulin resistance. It regulates insulin by 
promoting glucose uptake into the myocytes, suppressing gluconeogenesis in the 
hepatic cells and increasing fatty acid oxidation in both muscle and hepatic 
tissue. With the increase in adipose tissue, the adiponectin receptors become 
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resistant to adiponectin and there is a decrease in fatty acid oxidation, reduced 
insulin signaling and an eventual insulin resistance (reviewed by LeRoith, 2011).  
 
The exact mechanism for obesity causing hypertension is not fully understood, 
but it is postulated that the link is through insulin resistance. Hyperinsulinemia 
enhances sodium resorption through its effect on the distal renal tubules, 
resulting in hypertension. Another mechanism involves increased secretion of 
aldosterone due to elevated insulin, causing hypervolemia and ultimately 
contributing to hypertension (Barnett, Barnett and Kumat, 2009). Countless 
studies have shown the association between obesity and CKD through diabetes 
and hypertension, and other components of the metabolic syndrome (Stengel et 
al, 2003; Kramer et al, 2005; Locatelli, Pozzini and Vecchio, 2006). A number of 
studies have attempted to find a direct association between metabolic syndrome, 
which is characterized by abdominal obesity, high triglycerides, low HLDs and 
high blood pressure; and CKD, however it is difficult to differentiate the effect 
caused by each of the factors, the metabolic syndrome, hypertension and 
impaired glucose metabolism (El Nahas, 2005). Kurella, Lo and Chertow (2005) 
investigated the effect of type 2 diabetes and components of the metabolic 
syndrome on the development of CKD, and after adjusting for hypertension and 
diabetes there was still an increased risk of CKD among the study participants, 
suggesting that other conditions of the metabolic syndrome may be involved in 
the mechanism initiating CKD, however this is yet to be proven (Kurella, Lo and 
Chertow, 2005).  
 
1.5.3 Folk medicine 
 
Folk remedy usage is prevalent throughout Africa and Asia, and the effect of its 
intake on renal damage requires investigation in African populations as the 
medication is widely used in Africa. The use of folk medication is most popular 
amongst the poorer sections of society in the developing world. Over three-
quarters of the population in sub-Saharan Africa depend on traditional medicine 
as their primary source of health care, more than 60% of the Chinese use herbal 
therapy and a large part of the rural population in India relies on indigenous 
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medical systems that use herbs, ash and heavy metals (reviewed by Jha, 2009). 
The source and composition of the herbal remedies varies around the world but 
the origin of botanical ingredients is alike. The prescription and distribution of 
these remedies is done by community trained herbalists and the ingredients of 
the given mixtures are never tested for safety or toxicity. Aristolochic acid 
nephropathy is the most frequent herb-induced form of CKD. The toxic ingredient 
is aristolochic acid, which is a component of a Chinese herb, Aristolochia fangchi 
(reviewed by Jha, 2009). Common African plants associated with toxicity and 
acute and chronic renal failure, include the Cape Aloes, Callilepis laureola and 
the Securidacea Longepedunculata (Luyckx, Steenkamp and Stewart, 2005). 
The reasons suggested for consultation with traditional healers include the 
protection of a child, increased sexual potency, infertility treatment, removal of 
evil spirits, getting rich and protection against witchcraft. Many patients only 
resort to Western medicine after the use of folk treatment has failed, due to 
tradition and culture. The use of herbal remedies is often withheld by patients due 
to the fear of judgment, as there is much stigma attached to the use of folk 
medicine (Luyckx, Steenkamp and Stewart, 2005). True incidence of CKD due to 
nephrotoxic herbs remains uncertain.  
 
1.5.4 Genetic factors associated with CKD 
 
The role of genetics in the development of CKD has been an immense 
breakthrough that has partly elucidated the aggregation of kidney disease in 
families and populations. Many years of positional cloning studies have led to the 
identification and characterization of numerous genes and mutations in kidney 
diseases. It is clear that kidney diseases have a strong genetic component, and 
can therefore be classified into monogenic and polygenic CKD (reviewed by 
Hildebrandt, 2010). Rare single mutations causing monogenic kidney disorders 
have been identified and almost all demonstrate Medelian Inheritance patterns. 
The degree in which these genes cause the kidney disease depends on the 
mode of inheritance (reviewed by Hildebrandt, 2010). Monogenic recessive 
disorders have a tight genotype-phenotype correlation due to the full or high 
penetrance and usually manifest by adolescence, including autosomal recessive 
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polycystic kidney disease (ARPKD) and pediatric nephrotic syndrome caused by 
mutations in the nephrosis 2 (NPHS2) gene (Boute et al, 2000). An important 
factor of monogenic diseases is the fact that the mutation itself represents the 
primary cause of the disease. Dominant monogenic diseases develop in 
adulthood with a reduced genotype-phenotype correlation because of incomplete 
penetrance and varying expressivity such as glomerulocystic kidney disease 
(GCKD) and FSGS due to actinin alpha 4 (ACTN4), transient receptor potential 
cation subfamily 6 (TRPC6) and inverted forming 2 (INF2) mutations (Kaplan et 
al, 2000; Winn et al, 2005; Brown et al, 2010; reviewed by Hildebrandt, 2010). At 
the other end of the spectrum of causality, with very weak genotype-phenotype 
correlation, are polygenetic disorder mutations. Multiple mutated alleles in 
different genes have to act in concord to cause disease (reviewed by 
Hildebrandt, 2010). These diseases manifest in adulthood and are more frequent 
than monogenic diseases, with less heritability; there is more room for 
environmental changes. 
 
Linkage analysis has been successful in identifying renal disease-causing 
mutations with a mendelian mode of inheritance (reviewed by Friedman and 
Pollak, 2011). Linkage analysis is informative when investigating genes for rare, 
Mendelian, monogenic disorders for which there is strong familial risk, and for 
identifying loci that are strongly associated with complex diseases (reviewed by 
Hirschhorn and Daly, 2005). Linkage analysis makes use of the shorter distance 
between genetic loci, assuming that the closer they are positioned to each other, 
the more likely the variants are co-inherited, first described by A Sturtevant in 
1913. However, linkage analysis has failed to detect most of the polymorphisms 
associated with common CKD phenotypes (ESRD and DN, GFR, and 
albuminuria) (reviewed by Friedman and Pollak, 2011). Genome wide association 
studies (GWAS) were subsequently introduced, which allowed for the analyzing 
of the entire genome and identification of polymorphisms with small effects that 
might increase predisposition to common complex diseases (McCarthy and 
Hirschhorn, 2008). The drawback of this approach is the large amount of 
genotyping that is required. The number of polymorphisms that can be screened 
and the cost of the analyses can be reduced by genotyping one variant within a 
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haplotype (Lunetta, 2008). Another disadvantage is the marked difference in 
allele frequency between mixed populations, which results in the overestimated 
effect of polymorphisms within complex disease. This was resolved by 
introducing admixture mapping, also known as mapping of admixture linkage 
disequilibrium (MALD). This strategy is cost effective as it required studying 
2000-3000 markers, which is 200-500 times fewer than is needed for genome-
wide association analysis (Briscoe, Stephens and O’Brien, 1994; McKeigue, 
1998; reviewed by Darvasi and Shifman, 2005). The ability to detect haplotypes 
that contain a disease-associated polymorphism for a specific complex disease 
using MALD is maximised by analysing markers that are most divergent between 
the parent populations of the mixed ethnic group (for example, African and 
American in the case of the African-American group) (Briscoe, Stephens and 
O’Brien, 1994; Dean and Santis, 1994; McKeigue, 1998; reviewed by Smith and 
O’Brien, 2005; Darvasi and Shifman, 2005). Since the commencement of this 
genetic research, several genes have been implicated in CKD susceptibility, 
initiation and progression and its many risk factors, including UMOD, SHROOM3, 
TCF7L2, CUBN, ELMO1, Angiotensin gene, MTHFS, MTHFR, IL-1RA and 
APOL1. Additionally, it was through GWAS and MALD that specific haplotypes in 
the MYH9 locus were found to be associated with an increased risk for FSGS 
and CKD in African Americans and later hypertensive-, non-diabetic and diabetic-
ESRD (reviewed by Hildebrandt, 2010). 
 
The uromodulin (UMOD) gene is located on chromosome 16q12.3 and 
exclusively expressed in the renal tubular cells of the thick ascending Loop of 
Henle in the kidney (Hart et al, 2002). UMOD encodes for the Tamm-Horsfall 
protein (also called uromodulin), and although isolated almost 6 decades ago, the 
physiologic role of this protein remains unclear.  The increased concentration of 
uromodulin in urine has been associated with the development of CKD (Köttgen 
et al, 2010) and medullary cystic kidney disease 2 (Hart et al, 2002). The minor T 
allele at rs12917707 on the UMOD gene has been associated with a 20% 
reduced risk of CKD (Köttgen et al, 2009). These studies were all conducted in 
people of European decent, and it has not shown any reproducible results in 
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other populations. However in the Japanese population, UMOD polymorphisms 
have been associated withhypertension (Iwai et al, 2006).  
 
The SHROOM3 gene is found on chromosome 4q21.1 and codes for the actin-
binding protein, shroom3, which is important in apical epithelial constriction, and 
therefore regulation of the shape of epithelial cells (reviewed by Divers and 
Freedman, 2010). The rs17319721 A allele in the SHROOM3 gene has been 
associated with a lower GFR and lower urine albumin:creatinine ratio in the 
European and African populations (Ellis et al, 2010) 
 
The transcription factor 7-like 2 gene (TCF7L2) encodes the transcription factor 
4, which acts as a downstream effector in the canonical Wnt signaling pathway 
and has been strongly associated with type 2 diabetes risk and impaired glucose 
tolerance in the European, Asian and African populations (Köttgen et al, 2008). In 
all populations studied, the T allele of rs7903146 has been strongly linked with 
type 2 diabetes. Few other SNPs in TCF7L2 have shown reproducible 
association with type 2 diabetes (Cauchi et al, 2007). This gene is also 
significantly associated with CKD progression and function in individuals without 
diabetes in both American Caucasians and Africans. Kottengen et al (2008) 
showed that the rs7906195 C and rs7903146 T alleles have been associated 
with a 20% increase in CKD progression risk in Caucasians without diabetes, but 
only the rs7906195 has shown similar significant association in African 
Americans (Köttgen, 2008).  
 
Cubulin, product of the CUBN gene, is found in the apical brush border area of 
the proximal tubules in the kidney (Birn et al, 1997). Together with megalin and 
amnionless, cubulin regulates receptor-mediated endocytosis of low-molecular-
weight proteins (Christensen, Verroust and Nielsen, 2009). When cubulin is 
lacking or mutated due to variations in the CUBN gene, proximal tubular protein 
reabsorption is ineffective, resulting in proteinuria (reviewed by Böger and Heid, 
2011). This explains the association between the rs1801239 C allele and 
consistently higher urine albumin:creatinine ratio and microalbuminuria. The 
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significant association was observed in European and African individuals with or 
without diabetes and hypertension (Böger et al, 2011). 
 
The engulfment and cell motility 1 (ELMO1) gene is found on chromosome 7p14 
and is ubiquitously expressed but predominantly in the spleen and placenta 
(Shimazaki et al, 2005). The ELMO1 protein interacts with other proteins to 
promote phagocytosis of dying cells and cell shape changes (Gumienny et al, 
2001). Its association with type 2 diabetes was first reported in the Japanese 
population (Shimazaki et al, 2005), and later similar findings were obtained in 
African Americans in addition to having an effect on ESRD. An association with 
type 1 diabetes was also observed in the Caucasian population (Garrett, 
Pezzolesi and Korstanje 2010). Different regions of the ELMO1 gene are 
associated with the significant findings in different ethnic groups, with intron 18 in 
the Japanese population, intron 13 in the African American population and 
typically intron 16 in European Americans, with different polymorphisms 
producing the common DN phenotype (Divers & Freedman, 2010) 
 
The angiotensin-converting enzyme (ACE) is encoded by the angiotensin gene, 
which is localized on chromosome 17. ACE is a metalloenzyme which converts 
angiotensin I to angiotensin II, is a vasoconstrictor, and inactivates bradykinin, a 
vasodilator (Sayin et al, 2009). ACE is part of the renin-angiotensin system (RAS) 
that is involved in regulating blood pressure and fluid balance. Upregulation of 
RAS has been reported in CVD and also suggested to contribute to the 
development of CKD (Reveiwed by Wong, Kanetsky and Raj, 2008). RAS has 
also been implicated in the induction of cell proliferation and fibrosis, which 
affects development of CKD (Kagami et al, 1994). Polymorphisms in the 
angiotensin gene have been associated with an increased susceptibility or 
initiation of CKD in diseases such as Henoch-Schonlein purpura, diabetic 
nephrology and hypertension, as well as rapid progression of CKD (El Nahas and 
Levin, 2009). A deletion/insertion (I/D) polymorphism has been identified in intron 
16, which is believed to be responsible for about 50% of the variability in plasma 
ACE levels among individuals (Gumprecht et al, 2000). Particularly, a 
homozygous deletion (D/D) was associated with higher ACE levels, which in turn 
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was implicated in ventricular hypertrophy and increased carotid intima-media 
thickness in ESRD (Balkestein et al, 2001). The D allele has also been linked 
with a rapid decline of renal function (Gumprecht et al, 2000), and homozygous D 
carriers had a worse disease prognosis and developed CKD at a younger age 
(Baboolal et al, 1997; Luttropp et al, 2009). The role of the I/D polymorphisms 
was also reported in relation to ACE inhibitor treatment, in which I/I carriers with 
immunoglobulin A nephritis receiving this medication had a reduced progression 
to ESRD (Yoshida et al, 1995). 
 
SNP rs6495446 in the methenyltetrahydrofolate synthetase gene (MTHFS) has 
been associated with CKD in Caucasians, but the mechanism by which this leads 
to susceptibility, initiation, or the progression of CKD is not yet fully understood 
(El Nahas and Levin, 2009; Kottgen, et al, 2008). The MTHFS gene has been 
mapped on chromosome 15q25.1 and codes for the methenyltetrahydrofolate 
synthetase, which is responsible for tetrohydrofolate metabolism and helps in the 
biosynthesis of purines, thymidine and amino acids (El Nahas and Levin, 2009). 
Also involved in folate metabolism pathway is methenyltetrahydrofolate reductase 
(MTHFR), which catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate, a co-substrate for remethylation of homocysteine to 
methionine (reviewed by Födinger, Höri and Sunder-Plassmann, 2000). A review 
by Rao, Reddy and Kanagasabapathy (2008) reported higher levels of 
homocysteine in CKD patients, and speculated that this may accelerate the 
atherosclerotic process by inducing lipoprotein oxidation and endothelial injury. 
The 677C>T polymorphism in the MTHFR gene has been associated with 
diabetic nephropathy, with the T allele predominantly found in affected individuals 
with early onset DN who progressed to ESRD (Ksiazek, Bednarek-Skublewska 
and Buraczynska, 2004). The MTHFR gene has been mapped to 1p36.3 
(Goyette et al, 1994). 
 
Interleukin-1 receptor antagonist (IL-1Ra), encoded by the IL-1RN gene, is a 
protein of the interleukin 1 (IL1) family (reviewed by Dinarello, 1994). It is a 
competitive inhibitor of IL-1. Intron 2 of IL-1RN contains an 86-base pair variable 
number tandem repeat consisting of 2-6 repeats. The genes coding for IL-1Ra 
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and IL 1 are located near to each other on the long arm of chromosome 2. The 
less common allele of IL-1RN containing 2 repeats has been associated with an 
increased production of IL-1Ra protein and a decreased production of IL-1 
(Jaaskelainen et al, 2008). This 2-repeat allele has been associated with ESRD 
and CKD progression in patients with diabetes nephritis and glomerulonephritis 
(Luttropp et al, 2009). It has also been shown to play a role in the development of 
a severe clinical outcome of inflammatory diseases and increased risk for 
coronary artery diseases in patients with type 2 diabetes (Marculescu et al, 
2002).  
 
1.5.5 Nonmuscle myosin heavy chain (MYH9) and its association with CKD 
 
The MYH9 gene is located on the long arm of chromosome 22 at position 13.1, 
located from base pair 36 677 322 to base pair 36 784 062, approximately 110 kb 
with 41 exons (Kopp et al, 2008). This gene encodes for the myosin IIA heavy 
chain, a subunit of myosin IIA protein. Myosin IIA heavy chain consists of 1960 
amino acids and is 227kDa in size, with a globular head in N-term and a coiled-
coil tail in C-term (Schilwa, 2006). An actin binding site is found in the head 
region, interacting with actin, as well as a light chain binding site present in the 
long tail region. It is abundantly expressed in the kidney, platelets and liver and in 
smaller amounts in the thymus, spleen, intestine and cochlea. Within the kidney, 
it is expressed in the glomerulus, specifically the podocyte, peritubular capillaries 
and tubules. Myosin IIA heavy chain plays several physiological roles such as 
cytokinesis, cell motility and the maintenance of cell shape (Schliwa, 2006).  
 
More than 45 mutations have been found in the MYH9 gene, and implicated in a 
wide range of disorders that have subsequently been grouped and termed the 
MYH9-related disorder (Tzur et al, 2010). These disorders are characterized by 
large platelets and thrombocytopenia, both present from birth. The autosomal 
dominant giant-platelet disorders include May-Hegglin anomaly, Fechtner 
syndrome and Sebastian syndrome, all exhibiting dohle bodies within their 
leukocytes; and Epstein syndrome which is characterized by deafness and 
cataracts (Schliwa, 2006). Although the exact mechanism of the development 
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and progression of non-diabetic CKD by polymorphisms in the MYH9 gene is 
unknown, aggregation of abnormal myosin and damage to the cytoskeleton of 
the podocyte and tubular cells, and the rearrangement of the actin cytoskeleton, 
ultimately disrupting the filtration barrier, have been hypothesized (Johnstone et 
al, 2011). 
 
The initial discovery of the MYH9 gene variation increasing CKD risk was made 
in 2008 by Kopp et al, a study that demonstrated a high risk (7.5%) of developing 
ESRD in African-Americans compared to European Americans (2.1%). According 
to Kopp et al (2008), African-Americans have a disproportionate risk for certain 
CKD types, namely DN, HN, lupus nephritis, FSGS and HIVAN. The authors 
suggested that this observation could be partly explained by lifestyle, social-
economic status and clinical factors such as poor blood glucose or blood 
pressure control. Although diabetes and hypertension can be familial, with 
individuals from African decent having a greater risk of both, further making this 
ethnic group more susceptible to CKD, predisposing polymorphisms would better 
explain the large disproportion of the risk. The hypothesis of this 2008 study was 
that the fourfold increased risk for idiopathic FSGS and 18-50 fold increase in 
HIV-associated nephropathy would be associated with genetic variants that 
would be frequent and have strong effects in African Americans but would be 
infrequent in European Americans. The results of a mapping by admixture 
linkage disequilibrium (MALD) study done by this study group identified MYH9 as 
a functional and possible candidate gene. Their scan yielded a single prominent 
peak located on chromosome 22 with a logarithm of odds (LOD) score of 12.4. 
MYH9 was one of 35 genes that fell into the 95% interval of credibility of the 
MALD peak. The LOD score compares the likelihood of the genes in the 
chromosome 22 peak being linked; to the likelihood that the data obtained was 
purely by chance. A LOD score of higher than 3 is considered significant, 
signifying that the data is in fact linked (Morton, 1955). Twenty MYH9 SNPs were 
selected as they demonstrated a pronounced frequency difference between 
Yorubas (YRI) (a West African ethnic group) and European (CEU) populations 
from the International HapMap Project data. Three MYH9 SNPs located in intron 
23 (rs4821480, rs2032487 and rs4821481), were in strong LD, and thus termed 
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extended or E-1 haplotype. The LD refers to the occurrence or frequency of the 
combinations of alleles in a population (Li and Stephens, 2003). This may 
happen more or less often in the given population when compared to the number 
of times the allele combinations would occur should a random formation of 
haplotype be formed based on their frequencies. LD is commonly described 
using D’, with a range between -1 and 1 (Li and Stephens, 2003). The odds ratio 
(OR) ranged from 3.9 to 5.7 when comparing homozygous risk allele individuals 
and heterozygous risk allele individuals as opposed to an OR of close to 1 when 
comparing heterozygous and non-risk homozygous allele, clearly showing a 
recessive nature of these three intron 23 SNPs. Conversely, SNPs rs5756152, 
rs1005570 and rs16996677 had additive effects with higher ORs when 
comparing homozygous risk allele carriers to those harboring homozygous non-
risk allele individuals. The OR provides an estimate of the relationship between 
the binary variables (Bland and Altman, 2000). It enables one to examine the 
effects of other variables on that relationship using logistic regression and is 
useful in case-control studies. 
 
Kopp et al (2008) then did association studies with idiopathic and HIV-1-
associated FSGS, revealing seven significantly associated SNP results, including 
rs4821480 (p = 3 x 10-5) and rs5756152 (p = 1 x 10-7). The susceptible allele in 
all seven SNP’s was frequent in both African Americans (29 – 91%) and YRI (40 
– 97%) but much less frequent in European Americans (3 – 52%). Haplotype 
association showed that the strongest risk association with FSGS was for the E-1 
haplotype (p = 4 x 10-23). The E-1 haplotype had a frequency of 60% in African 
Americans but only 4% in European Americans. Consistent with this result, the E-
2 haplotype was the most frequent in European Americans (69%) and showed 
the significant protective effect (p = 0.008). The four SNPs in the E-1 haplotype 
showed modestly significant associations between FSGS and European 
Americans, although the E-1 haplotype itself didn’t boast any significance. 
Additionally, association studies were done regarding H-ESRD. Nine MYH9 
SNPs, including rs5756152 (p = 0.0002) as well as the E-1 haplotype 
(rs4821480, p = 0.002) showed significant associations with H-ESRD, consistent 
with the FSGS direction. Lastly, during survival analysis studies, haplotype E-1 
showed no significant association with progression to ESRD.  
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Following this important finding, a further study was done by Freedman et al in 
2009 in a larger group of unrelated African Americans with H-ESRD, which 
demonstrated an association between the E-1 haplotype and hypertensive 
African Americans (p = 4.52 x 10-12).  A novel second haplotype, termed L-1, 
consisting of rs7078, rs12107, rs735853 and rs5756129, also showed significant 
association with H-ESRD in a recessive model. The study demonstrated that 
rs5756152 was independently associated with H-ESRD even after adjusting for 
the E-1 and L-1 haplotypes.  In addition, the study demonstrated rs5756152 (p = 
2.92 x 10-5) and rs12107 (p = 0.01) exhibited independent evidence for 
association.  The evidence of association of rs12107, rs4821480, and rs5756152 
with CKD was further replicated in other studies. Kao et al (2008) conducted a 
MALD analysis that revealed an association between MYH9 SNPs that included 
rs12107 (p = 3.64 x 10-3), rs4821480 (p = 1.72 x 10-11) and rs5756152 (p = 4.49 x 
10-9) and non-diabetic ESRD. These authors also detected an association 
between the investigated MYH9 SNPs and both hypertensive and FSGS ESRD.  
Additional genome-wide analysis has supported the initial MYH9 findings of 
association with hypertension and albuminuria in African Americans and non-
diabetic ESRD in Hispanic Americans (Behar et al, 2010). Behar et al (2010) 
identified the F-1 haplotype, comprising of SNPs rs16996674, rs16996677 and 
rs11912763, which has a statistically significant association with non-diabetic 
ESRD and O’Seaghdha et al (2011) identified the S-1 haplotype that spans intron 
13 -15 of the MYH9 gene, which also showed association with an even greater 
risk of CKD. 
 
There has been much speculation following these initial findings, with a few 
articles concluding that the MYH9 and renal disease association is non-existent. 
This uncertainty stemmed from the discovery of the second gene encoding 
apolipoprotein 1, which was also mapped in chromosome 22, near the MYH9 
locus. Genovese et al (2010) determined that the E-1 haplotype of the MYH9 
gene, the best predictor of renal disease in previous studies, was present in most 
haplotypes containing the G1 and G2 alleles of the APOL1 gene (E-1 was 
present in 89% of haplotypes carrying G1 and 76% of haplotypes carrying G2), 
which were found to be stronger risk factors for CKD in African Americans than 
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polymorphisms within the MYH9 gene. In contrast to the MYH9-CKD associated 
SNPs that seem to have no apparent functional defect, the three APOL1 
polymorphisms alter the amino acid sequence of the encoded protein, suggesting 
functionality: S342G and I384M referred to as G1, and a 6-base pair deletion that 
removes N388 and Y389 referred to as G2. The APOL1 polymorphisms were 
initially reported to have a strong effect on FSGS risk, but were later found to be 
strongly associated with hypertensive-ESRD (Genovese et al, 2010). These 
polymorphisms also proved to be stronger genetic factors in HIVAN compared to 
FSGS and H-ESRD (Kopp et al, 2010). Studies done in African populations 
(Ethiopia, Cameroon, Congo, Ghana, Malawi, Mozambique and Sudan) found 
0% occurrence of the APOL1 G1 and G2 alleles in HIV affected individuals with 
no HIVAN from Ethiopia, further suggesting that APOL1 may play a role in the 
development of HIVAN in this population group (Tzur et al, 2010). Importantly, 
APOL1-mediated kidney disease risk showed an autosomal-recessive 
inheritance rather than an additive pattern that is typical of most common 
complex disease. Although aspects of the APOL1-CKD association is compelling, 
there still remains no evidence that APOL1 polymorphisms are strongly 
associated with CKD and data from the human protein atlas suggest that APOL1 
is not even expressed in the glomeruli (Johnstone et al, 2011). The results from a 
study done by Tzur et al (2010), suggest that APOL1 polymorphisms may have 
arisen from positive selection due to Trypanosomiasis, which may explain the 
high allele frequency in African ancestries (Genovese et al, 2010). Humans are 
resistant to Trypanosoma brucei due to the lysis effect of the APOL1. However, a 
subspecies of this parasite that later emerged, is resistant to APOL1-mediated 
lysis and can only be destroyed by the presence of the G1 and G2 
polymorphisms, which inactivates the virulence factor of the T. brucei 
rhodesiense.  
 
This additional and post-APOL1 genetic association discovery regarding the 
MYH9 gene as well as the fact that this gene is already implicated in several rare 
inherited syndromes with glomerular involvement makes it impossible for CKD 
and MYH9 gene variation association to be ruled out (Nelson et al, 2010). 
Indeed, the genetic involvement of chronic diseases, such as CKD, is complex 
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and undoubtedly involves many genes with multiple interactions, and it may be 
postulated that the MYH9 and APOL1 genes complement each other (Freedman 
et al, 2011). The compelling evidence of MYH9 polymorphisms and their renal 
disease associations led to the motivation for this study, particularly in the mixed 
ancestry ethnic group of South Africa due to its admixture nature that may be 
similar to that of African Americans.  
 
1.6 SIGNIFICANCE OF RESEARCH 
 
It has been estimated that CKD affects approximately 1 in 10 adults or over 500 
million people worldwide (Zhang and Rothenbacher, 2008). However, this 
prevalence only reflects the burden of the disease in developed countries. In low-
income countries, including South Africa, the burden of chronic disease including 
CKD is also increasing but the prevalence of CKD to date is largely unknown due 
to no recent published data. The last reliable report of the South African Dialysis 
and Transplant Registry (SADTR) in 1994 indicated that 3399 patients were on 
treatment for ESRD, with 754 new patients having commenced therapy in that 
year (SADTR, 1994). It is likely that this number has risen since then and is 
therefore not a true representation of the actual prevalence. Diabetes, 
hypertension and glomerulonephritis are the three leading causes of CKD. With 
the increasing burden of obesity, type 2 diabetes and hypertension, it is expected 
that the incidence of ESRD will mirror that of these three diseases. This 
observation has dire implications for the developing world where the burden of 
diabetes is projected to increase by 250% by year 2030 (Wild et al, 2004). It is 
estimated that by 2030, more than 70 percent of patients with ESRD will be 
residents of developing countries (Barsoum, 2009).  
 
The increasing prevalence of diabetes in most populations is partly due to the 
increase in the prevalence of obesity. Currently, more than one billion adults are 
overweight, with at least 300 million of them deemed clinically obese (WHO, 
2006). Obesity is also associated with FSGS, a combination which has poor long 
term prognosis with one half of the patients ultimately developing advanced renal 
failure (Praga et al, 2001).  In South Africa, where 29.2% of men and 56.6% of 
women are overweight or obese (Puone et al, 2002), diabetes is believed to 
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occur in 10% to 16% of adults although prevalence rates of up to 25% have been 
reported recently in some age groups (reviewed by Katz, 2005). Hypertension, on 
the other hand, is considered a cause of ESRD in 34.6% of Blacks, 20.9% of 
Mixed Ancestry, 13.9% of Indians, and 4.3% of Whites (reviewed by Katz, 2005). 
Several studies have also reported a high prevalence of diabetes in the mixed 
ancestry ethnic group, from 10.8% in 1996 (Levitt et al, 1999) to 25.6% in 2008 
(Erasmus et al, 2012). South Africa has an additional burden of HIV, which has 
affected 19.9% of the adult population and contributes to 30% of deaths and 
numerous cases of HIVAN (reviewed by Katz, 2005). These risk factors, together 
with a high HIV/CKD prevalence result in a large burden of CKD in this country. 
Earlier interventions for CKD would be beneficial but the lack of knowledge on 
the number of affected people and those at risk of developing the disease 
hinders the adoption of appropriate preventive measures that may be useful. 
Establishing predisposing factors for CKD will enable early identification of 
individuals or groups of people who might benefit most from early screening, 
detection and intervention to prevent the initiation of CKD or delay progression to 
ESRD and associated cardiovascular risk. 
 
1.7 CONCLUSION 
 
Chronic kidney disease is a silent epidemic, the 12th highest cause of death 
worldwide. Despite adjustment for the many identified non-modifiable and 
lifestyle factors, certain populations still have a large disproportion of risk for CKD 
that could only be explained by predisposing polymorphisms. The role of genetics 
in the development of CKD has been an immense breakthrough that has partly 
elucidated the aggregation of kidney disease in families and populations. 
Polymorphisms in the MYH9 gene have been associated with FSGS, H-ESRD, 
HIVAN and non-diabetic ESRD in the African American population with SNPs 
rs5756152, rs4821480 and rs12107 showing independent association. The 
mixed ancestry population in the Bellville South area in Cape Town, South Africa, 
is a population of interest due to the similar ancestry of both African and 
Caucasian. Establishing predisposing factors for CKD will allow for early 
identification of individuals of groups of individuals who would benefit from early 
screening, detection and intervention.  
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CHAPTER 2 
[Research Methodology] 
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2.1 INTRODUCTION 
 
As described in Chapter 1, research into the association between polymorphisms 
in the MYH9 gene and CKD has been of great significance in the African 
American population. This has led to an increased interest in the mixed ancestry 
population of Bellville South, Cape Town, South Africa. The research design and 
methodology in this study is aimed at determining if there is an association 
between CKD and its related co-morbidities and MYH9 polymorphisms in the 
mixed ancestry subjects residing in the urban township of Cape Town, through 
genotyping. This chapter will detail the research setting, study design; and 
population characteristics. The collection of data and participant medical 
information was obtained via questionnaires, physical examinations and 
biochemical analyses, with details given. Protocols of laboratory work required to 
extract DNA and genotype the samples are described and finally the statistical 
methods to be used will be detailed.  
 
2.2 RESEARCH SETTING 
 
In the Western Cape, the Bellville South community matched the requirements of 
the mixed ancestry population required for this study. Bellville South is located 
within the northern suburbs of Cape Town, South Africa. It is traditionally a 
community of a mixed ancestry ethnic population group formed in the late 1950s. 
The area, often referred to as a township, is an underdeveloped urban residential 
area that was previously reserved for non-Caucasians including the mixed 
ancestry group. The population has ancestry from Khoisan, African, European 
Caucasian and a small amount of Asian populations (Quintana-Murci et al, 2010). 
According to the 2001 population census (the latest census done in Bellville), its 
population stands at approximately 26 758 with the mixed ancestry group 
accounting for 80.48% (21 536). The target population for this study were 
subjects between the ages 35 – 65 years and their number was estimated to be 6 
500 (City of Cape Town Census, 2001), however other age groups were also 
included due to the higher CKD prevalence observed across all age groups.  
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2.3 RESEARCH DESIGN AND STUDY POPULATION  
 
The subjects in the study were selected from a main database from the Obesity 
and Chronic Diseases of Lifestyle Research Unit based at Cape Peninsula 
University of Technology, the main research project. This was a cross-sectional 
study aimed at establishing a cohort that can be followed up for insulin resistance 
and its sequel in randomly selected mixed ancestry. The data presented here was 
collected from mid-January 2008 to March 2009. Using a map of Bellville South, 
random sampling was conducted as follows: From a list of streets from each 
stratum, the streets were then classified as short, medium and long based on the 
number of houses within each street. Streets with houses ≤ 22 were classified as 
short, houses 23–40 as medium and long streets were those with > 40 houses. A 
total of 16 short streets representing approximately 190 houses, 15 medium 
streets representing approximately 410 houses and 12 long streets representing 
approximately 400 houses were randomly selected across the different strata. 
From the selected streets, all household members meeting the selection criteria 
were eligible to participate in the study. Community authorities requested that 
participants outside the random selection area benefit from the study; these were 
also included, but given a different code. Recruited subjects were visited by the 
recruitment team the evening before participation and reminded of all the study 
instructions. The instructions included overnight fasting, abstinence from drinking 
alcohol or consumption of any fluids in the morning of participation. Furthermore, 
participants were encouraged to bring along their medical/clinic cards and/or 
drugs they were currently using.  
 
2.4 INCLUSION/EXCLUSION CRITERIA 
 
The study population consisted of mixed ancestry participants residing in the 
Bellville South area, who consented to participate and gave blood for genetic 
analysis in addition to a medical history if necessary. The main research project 
consisted of 1254 participants however only a total of 724 subjects were included 
in this study, comprising of 526 random subjects between the ages 35 - 65 years 
and 198 voluntary subjects, age range 16 – 95. Ten subjects were from other 
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ethnic groups, whilst five did not consent to blood sampling and were excluded 
resulting in a total of 941 participants. Individuals with GFR of <60 ml/min and 
ACR of 17-250 mg/g for men or 25-355 mg/g for women were included as a case 
group. Those with GFR ≥ 60 ml/min were included as a control group. The control 
group was matched to the case according to age, gender, and ethnicity (mixed 
ancestry).  
 
2.5 SAMPLE SIZE 
The main research project consisted of 1254 participants from which the study 
population of the present project was selected. The study reported a CKD 
prevalence of 29.6% (unpublished data) according to the MDRD equation. To 
obtain statistically significant observations on allelic distributions and adequate 
power for association tests between diabetes, hypertension and obesity-related 
traits and genotypes given the reported prevalence, the number of a control group 
was chosen based on a 1:1 case-control ratio. In order to successfully analyze 
association studies, the sample size must be sufficiently large to create enough 
statistical power to reduce the probability of generating false-positive associations 
(Berry and Ho, 1988). The following guided our genotype sample size calculation: 
the number of people in the desired population, the estimated population 
variance, the desired precision, the confidence interval and the estimated 
response rate. The sample size was calculated as a minimum of 704 participants 
needed in order for this study to display a 95% confidence interval and a 3% 
margin of error. 
2.6 DATA COLLECTION 
To obtain the medical information and samples of the participants, a detailed 
protocol describing data collection procedures (questionnaires and physical 
examination) was developed. The team members, consisting of professional 
nurses and field workers, were trained, and a pilot study in a neighboring 
community with similar demographics was performed to validate the 
questionnaire and to synergize the workflow. A supervisor was allocated for each 
team to monitor the performance of the personnel and calibrate equipment 
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according to a standard protocol. In addition, weekly meetings were held to 
assess progress, solve problems and re-train the research team (if necessary). A 
questionnaire designed to retrospectively obtain information on lifestyle factors 
such as smoking and alcohol consumption, physical activity, diet, family history of 
CVD and diabetes mellitus (DM), demographics etc. was administered by trained 
personnel (appendix B). The questionnaire was adapted from several existing 
standards and recognized sources (Bradshaw et al, 1995; Ewing, 1984) and was 
also pre-tested in a neighboring community with similar demographics. 
Information about medication taken by participants was also obtained through 
clinic cards and record of drugs that participants brought to the study site. The 
more detailed the information retrieved, the more accurate and complete the 
database, allowing for more association tests during statistical analysis. 
2.6.1 Anthropometric measurements 
 
Clinical measurements obtained included: height, weight, hip and waist 
circumferences and blood pressure. Measurements were carried out by qualified 
healthcare professionals who underwent training to standardize all measurements 
prior to the commencement of the study. Blood pressure measurements were 
performed according to World Health Organization (WHO) guidelines (WHO, 
1999). Measurements were performed using a semi-automatic digital blood 
pressure monitor (Rossmax MJ90, USA) on the right arm, in sitting and 
ambulatory position. After a 10 minute rest period, three readings were taken at 5 
minute intervals and the lowest of the three readings was taken as the blood 
pressure. Weight was determined on a Sunbeam EB710 digital bathroom scale, 
which was calibrated and standardized using a weight of known mass. Weight 
measurements were recorded to the nearest 0.1 kilograms and taken with each 
subject in light clothing, without shoes and socks. Height was recorded in 
centimeters to one decimal place using a stadiometer, with subjects standing on a 
flat surface at a right angle to the vertical board of the stadiometer. Body Mass 
Index (BMI) was calculated as weight per square meter (kg/m2). Waist 
circumference was measured using a non-elastic tape at the level of the 
narrowest part of the torso as seen from the anterior view. When difficult to 
observe the waist narrowing, especially in obese subjects, the waist 
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circumference was measured between the ribs and the iliac crest. All 
anthropometric measurements were performed three times and the average 
measurement used for analysis.  
 
2.6.2 Biochemical analyses 
 
All participants, except the self-reported type 2 diabetic subjects (confirmed by 
either medical card record or drugs in use) underwent a 75g oral glucose 
tolerance test (OGTT) as prescribed by the WHO, with fasting blood glucose in all 
participants. Categories of glucose tolerance were defined using the 1998 WHO 
criteria (WHO, 1999). Blood samples were transported daily in an ice-pack box for 
processing at the Metropolis Private Pathology Laboratory (Century City, Cape 
Town). Serum creatinine was determined using the kinetic-Jaffe reaction (Cobas 
6000, Roche Diagnostics, USA) and the result used to determine the glomerular 
filtration rate using the MDRD and CKD-EPI formulae. Plasma glucose was 
measured by enzymatic hexokinase method (Cobas 6000, Roche Diagnostics, 
USA). Glycosylated hemoglobin (HbA1c) was assessed by turbidimetric inhibition 
immunoassay (Cobas 6000, Roche Diagnostics, USA). This method is National 
Glycohaemoglobin Standardization Programme (NGSP) certified according to 
Roche Diagnostics. High density lipoprotein cholesterol (HDL-c) and triglycerides 
(TG) were estimated by enzymatic colorimetric methods (Cobas 6000, Roche 
Diagnostics, USA). Low density lipoprotein cholesterol (LDL-c) was calculated 
using Friedwald’s formula. Serum cotinine was measured by chemiluminescent 
assay (Immulite 1000, Siemens, Germany). This laboratory was accredited and 
performed all the necessary and required daily, weekly and monthly internal and 
external quality control. 
 
2.6.3 Data management 
 
To maintain patient confidentiality, all data captured sheets containing clinical and 
demographic info of each patient were coded by a study number and the 
specimen labeled accordingly, thus any info leading to the identity of the subjects 
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was kept separately. All consent forms and questionnaires were stored in 
confidential files and securely locked away.  
 
2.7 GENETIC ANALYSIS 
 
The genetic analysis of a set of samples requires DNA extracted from venous 
blood from each participant. The DNA quality and purity is determined to check 
viability of further testing. The genotyping of individuals for a specific 
polymorphism can be done using polymerase chain reaction (PCR) techniques. 
These methods require optimization for each specified polymorphism. In the 
present study, genotyping was conducted using real-time PCR (qPCR). Different 
amplification patterns obtained that represented each of the three genotypes 
were validated by conventional PCR, followed by automated sequencing. 
 
2.7.1 DNA extraction 
 
Venous samples were collected from consented subjects by professional medical 
nurses in Ethylenediamine Tetra acetic Acid (EDTA) tubes. These samples were 
transported to the laboratory at room temperature but were stored at – 20˚C as 
the extraction could not be done immediately. The modified salting out procedure 
was used to extract the genomic DNA from the venous samples. Solution make-
up can be found in Appendix D. A volume of 5-8 ml of whole blood was 
transferred from the EDTA tube into a 50 ml Falcon tube. Cold lysis buffer was 
adjusted according to the volume of blood used (according to the procedure, 30 
ml of cold lysis buffer for every 10 ml of blood) and added to a final volume of 40 
ml. All reagents used in subsequent steps were adjusted accordingly. This 
mixture was placed on ice for 15 minutes and inverted every 5 minutes to allow 
the contents to mix thoroughly. The mixture was then centrifuged at 1500rpm for 
10 minutes at 4˚C (J-6M/E centrifuge, Beckman, UK). The supernatant was 
carefully discarded and the pellet resuspended in 0.9% Phosphate Buffered 
Saline. This was followed by centrifugation at 1500 rpm for 10 minutes after which 
the supernatant was discard and the pellet resuspended in nuclear lysis buffer, 
0.3 mg/ml Proteinase K and 1% Sodium Dodecyl Sulphate.  The contents were 
mixed well and incubated at 55˚C overnight. The following day, 6 M NaCl was 
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added to the solution and the tubes were shaken vigorously for 1 minute. The 
mixture was centrifuged at 2500 rpm for 30 minutes. The supernatant containing 
the DNA was transferred to a clean Falcon tube, and the pellet discarded. The 
supernatant was vortexed for 15 seconds, and centrifuged at 2500 rpm for 15 
minutes. The subsequent supernatant was transferred to a clean Falcon tube, 
leaving behind the pellet and any foam. Cold 99.9% ethanol was added to each 
tube and agitated to precipitate the DNA. Using a sterile pipette, the DNA was 
pulled out of the Flacon tube, placed in a clean 1.5 ml eppendorf tube and 
washed with cold 70% ethanol. All tubes were centrifuged using a bench top 
microcentrifuge (Microcentrifuge® Lite, Beckman Coulter™, USA). This ‘washing 
step’ was repeated until the pellet of DNA was clear. The ethanol was discarded, 
tubes left at room temperature to dry and depending on the size of the pellet, 200 
– 800 μl of 1X Tris Ethylenediamine tetra acetic acid (TE) buffer was added to 
dissolve the DNA. All tubes were shaken at room temperature using a rotator, to 
dissolve the DNA pellet.  
 
2.7.2 DNA quality 
 
DNA purity and concentration was tested using the NanoDrop® ND-100 
spectrophotometer system. The NanoDrop® spectrophotometer used ultraviolet 
visible (UV/VIS) to accurately determine nucleic acid concentration in a sample, 
recorded in nanograms per microlitre (ng/μl). Those samples with high 
concentrations were diluted to obtain a final concentration of 200 ng/μl. The 
quality and purity of the DNA samples was also measured by measuring the ratio 
of absorbance at 260 nm and 280 nm. Purified DNA should give a result of ~1.8 
from the 260/280 ratio measurement. A deviation of this ratio is normally 
indicative of contaminants.  
 
2.7.3 Conventional polymerase reaction and sequencing 
 
The aim of PCR is the continuous, exponential, semi-conservative replication of a 
well-defined DNA region present in the template DNA leading to the accumulation 
of large quantities of specific target DNA product (Van Pelt-Verkuil, van Belkum 
and Hays, 2008). PCR was first described in 1985 and two key improvements in 
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the PCR process have since improved the technique, run time and convenience 
(Van Pelt-Verkuil, van Belkum and Hays, 2008). The process initially relied on 
non-thermostable DNA dependent DNA polymerase which became heat 
inactivated after every PCR cycle. The addition of thermostable DNA 
polymerases meant the laborious task of adding fresh enzyme after each cycle 
was eliminated. This reduced the time required to perform the assay and the 
likelihood of cross-contamination. Secondly, machines, thermocyclers, which 
could heat and cool the sample automatically, eliminated the need for several 
separate water baths.  
 
DNA to be amplified is initially removed from the nucleus of the cells via DNA 
extraction. The secondary and tertiary structures are then removed via heating 
the DNA, the denaturation step (Van Pelt-Verkuil, van Belkum and Hays, 2008). 
The double stranded DNA is separated by the heat into single stranded DNA 
strands, by the breaking of the hydrogen bonds between the complimentary base 
pairs on the opposite strands. The specific melting temperature (Tm) is dependent 
on the length of the DNA strand and the base composition, with Guanine-
Cytosine rich DNA melting at a higher temperature than Adenine-Thymine rich 
DNA (Van Pelt-Verkuil, van Belkum and Hays, 2008). Following melting, the DNA 
binding sites for the subsequent annealing stage are exposed. Specifically 
designed and synthetically synthesized oligonucleotides act as primers for the 
DNA polymerase enzyme. Two primers are required, one complementary to the 
sense strand and the other complementary to the non-sense strand. The primers 
determine the specificity of the PCR and the length of the DNA region to be 
amplified, and initiate the DNA replication (Van Pelt-Verkuil, van Belkum and 
Hays, 2008). The extension step of the PCR process requires free 
deoxynucleotide triphosphate molecules, namely adenine, guanine, cytosine and 
thymine. These are incorporated into the growing strand by the DNA polymerase. 
Their energy rich triphosphate section is utilized by the DNA polymerase to 
catalyse a phosphodiester link between the 3’-hydroxy terminus of the primer or 
the previous added deoxynucleotide triphosphate molecule (Van Pelt-Verkuil, van 
Belkum and Hays, 2008). Hydrogen bonds between the complementary base 
pairs on the adjacent strands are formed, and complete an amplification cycle. To 
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yield a high concentration of the amplified product, this cycle is repeated many 
times. Successful amplification requires added chemicals, specifically 
magnesium, a cofactor of DNA polymerase, and sodium chloride to maintain a 
correct reaction pH. The reaction temperatures, incubation times and number of 
cycles depend on the specific primer and the kit used to make up the master mix.   
This technique was used with automated sequencing as a quality control 
measure to validate the reliability of the real-time PCR technique. It was also 
used for identifying positive controls that could be incorporated in every qPCR. 
Thirteen samples were selected from the study population for sequencing. 
 
Oligonucleotide primers (Table 2.1) for amplifying the regions containing the three 
SNPs were designed following primer design guideline using Primer3plus and 
Integrated DNA Technologies (IDT) programs. The three SNPs selected are 
located in the following MYH9 regions: rs5756152 is found in intron 12 at 
bp65042418, rs4821480 in intron 23 at bp35025193 and rs12107 in exon 41 at 
bp35007928. Designed primers were checked for occurrence of dimers and 
hairpin loops using the IDT. Furthermore, primers were submitted to the National 
Centre for Bioinformatics Institute (NCBI) primer Basic Alignment Search Tool 
(BLAST) for possible non-specific binding. Primer sequences were analyzed for 
the presence or absence of polymorphisms that may inhibit amplification of 
corresponding gene regions.  
 
Table 2.1 Oligonucleotide primers and their characteristics for amplifying MYH9 
regions containing SNPs of interest. 
 
Primer name Sequence (5'-3') length in bases  Tm  GC content 
rs4821480_For AGC ACA GAA CAC TTG CTA GCC TCA 24  60.2 ºC 50.0 % 
rs4821480_Rev AAT CCT TTC TCA CCC AAG CCC ACA 24  60.5 ºC 50.0 % 
rs5756152_For  CTC CTG ACC TCA AG CAA TCT G 21  60.0 °C 52.4 % 
rs5756152_Rev CAT CGG GAT CCT GGA CAT T 19  60.7 °C 52.6 % 
rs12107_For GAT TCC TCC CCA CCC TGT 18  59.7 °C 61.1 % 
rs12107_Rev CCT CTA ACG CTC TGG CTG TC 20  60.2 °C 60.0 % 
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The PCR protocol was prepared in a sterile environment using Bioline Taq PCR 
kit and nuclease-free tubes and tips as follows: a total volume of 50 μl reaction 
mixture contained 1x buffer, 1mM magnesium chloride, 5% DMSO, 0.3mM dNTP 
mix, 0.24 M each of the forward and reverse primers, 0.1μl of 5U/μl Bio Taq, and 
nuclease-free water to obtain a final volume. The prepared PCR master mix was 
aliquoted to separate 0.2 ml tubes and 0.25 μg/μl of the DNA template was added 
to each tube. A non-template control was included in every PCR run to check the 
presence/absence of contamination. The gene regions were amplified in a Perkin 
Elmer 2720 thermal cycler (Applied Biosystems, USA) as follows: initial 
denaturation at 94°C for 2 minutes, 35 cycles of denaturation at 94°C for 30 
seconds, annealing at 55°C for 30 seconds, extension at 72°C for 30 seconds, 
and final extension at 72°C for 2 minutes. All amplicons were electrophoresed on 
a 2% agarose gel and visualized in a GelDoc system (BioRad, GmbH, Germany). 
 
All amplicons were purified with a mixture of exonuclease I and shrimp 
phosphatase, and then sequenced using the BigDye® Terminator version 3.1 
Cycle sequencing kit (Applied Biosystems) according to the manufacturer’s 
instructions. The sequence reaction mixture for each primer was prepared 
separately as follows: each primer to be used was diluted to 1.3 μM, and was 
mixed with 3 l amplicon solution, and 4 l BigDye® Terminator mix (2.5x), and 
BigDye® Terminator buffer (5x) or nuclease-free water to a final volume of 10 l. 
The sequencing reaction was conducted according to the manufacturer’s 
instructions, and resolved on an ABI 3130X ® Genetic Analyzer (Applied 
Biosystems, USA) at the Central Analytical Facility, University of Stellenbosch. 
The sequencing data was analysed using the Geospiza’s FinchTV version 1.4 
software programs.  
 
2.7.4 Real-time polymerase chain reaction 
 
PCR assays have undergone significant changes in the last decade. qPCR is a 
PCR-based technique used in DNA amplification and simultaneous quantification 
of the product (Mackay, 2007). It is sensitive, specific, fast and a closed system. 
The monitoring of the accumulation of the amplicon is made possible by the 
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addition of molecules with fluorescent potential that attach to the primer, 
oligoprobes or the amplicon (Mackay, 2007). The detection method may be non-
specific fluorescent dyes that bind to any double stranded DNA, increasing in 
fluorescence as the number for double stranded DNA molecules increases; or 
sequence specific DNA probes that are labeled with a fluorescent reporter which 
permits detection only after hybridization of the probe with its complementary 
DNA target (Van Guilder, Vrana and Freeman, 2008). Real-time PCR allows for 
the quantification of the products during the PCR cycles, allowing for gene 
expression analysis (Applied Biosystems, 2005). The level of fluorescence as 
opposed to the amount of PCR product is measured. An amplification plot is used 
to display the fluorescence over the cycles. For allelic discrimination, the 
fluorescent results are viewed once the cycles are completed, hence end-point 
qPCR (Applied Biosystems, 2005). It is used to determine the genotype of a 
sample, allowing for the differentiation of a SNP. This was the required method 
for this study. Due to the determination of two alleles, a specific, fluorescent, dye-
labeled probe for each allele is needed. The probes contain different fluorescent 
reporter dyes to differentiate between the amplification of each of the alleles. 
There are many dyes available, including VIC and FAM. VIC has an emission 
maximum of 554 nm, thus emitting a green-yellow color and in this study, 
measures the minor allele presence or absence (Life Technologies, USA). FAM, 
6-carboxyfluorescein, is the most commonly used fluorescent dye and fluoresces 
blue in colour at 517 nm. 
 
The study population was genotyped on the BioRad MiniOpticon Real time PCR 
system (Biorad, Germany) using TaqMan SNP genotyping assay (Applied 
Biosystems, USA) that was designed for each SNP, and data analyses conducted 
using a corresponding software (CFX Manager software). The initial step was to 
test the assay, and optimize it if necessary. The assay was bought ready-to-use 
and optimized from Applied Biosystems. However, a test run was recommended 
to make sure that the data generated was reliable for further analyses. For every 
run, a positive control (any of the samples with known genotypes according to 
sequencing results) was included plus at least 3 non-template controls. The real-
time PCR master mix was prepared according to the manufacturer’s instructions. 
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2.8 STATISTICAL ANALYSIS 
 
General characteristics of the study group are summarized as count and 
percentage for dichotomous and as median and interquartile range (IQR) for 
quantitative traits, as some of the distributions were skewed.  Traits were log-
transformed to approximate normality, where necessary, prior to analysis.  Linear 
models were used for the analysis of quantitative traits and logistic regression 
models for dichotomous traits.  Using models enabled us to adjust all analyses for 
known confounders’ age and gender (where possible). 
 
Additive allelic association of each SNP was compared with each trait, between 
participants with and without DM (interaction between DM and SNP on trait), after 
adjusting for age and gender. The additive allelic association of each SNP was 
also tested with each trait in the combined group, while adjusting for age and 
gender. These models provided the effect sizes and p-values reported in the 
results section.  Results corresponding to p-values below 5% are described as 
significant. Multiple testing was not adjusted for. Analyses were done in R, a 
language and environment for graphics and statistical computing, freely available 
from http://www.R-project.org. The R package genetics was used for genetic 
frequency distributions, Hardy-Weinberg Equilibrium (HWE) and LD testing. The 
HWE describes the equilibrium at a single locus in a randomly mating population 
(Gillespie, 2004). Hardy-Weinberg frequencies details unchanged genotype 
proportions in a large population from generation to generation should there be 
no evolutionary forces such as mutation, migration and selection (reviewed by 
Crow and Dove, 1998). It allows for the prediction of genotype frequencies from 
the knowledge of gene frequencies.  
 
2.9 ETHICAL CONSIDERATIONS 
 
The study was approved by the Cape Peninsula University of Technology, 
Faculty of Health and Wellness Sciences (Project number: CPUT/HW-REC 
2008/002 and CPUT/HW-REC 2010/H017) and the University of Stellenbosch 
Ethics Committee (N10/05/142) (Appendix A). The study was conducted 
Stellenbosch University  http://scholar.sun.ac.za
 57 
 
 
according to the Code of Ethics of the World Medical Association (Declaration of 
Helsinki). All participants signed written informed consent forms after all the 
procedures had been fully explained in the language of their choice (Appendix C). 
The consent form included the agreement for obtained blood samples to be 
stored and used for biochemical tests and genetic analyses. In addition, 
permission was also sought from other relevant authorities such as the city and 
community authorities. These authorities granted permission to operate in the 
community and also to make use of designated places such as community halls 
or nearby schools for data and sample collection. 
 
2.10 CONCLUSION 
 
The area of Bellville South in Cape Town is an underdeveloped urban residential 
area that was previously reserved for non-Caucasians, including the mixed 
ancestry population. This population consists of African, Khoisan, European and 
some Asian ancestry. It is this mixed ancestry that prompted the selection of this 
population and research setting as it met the requirements of interest of research 
into the MYH9 gene polymorphisms in the African American population. Following 
participant recruitment, anthropometric measurements and biochemical analyses 
were obtained. Samples were genetically analyzed from the initial DNA 
extraction, followed by genotyping and subsequently statistical analyses. The 
research objectives detail participant genotyping and analysis of the frequency 
and association results. This study design and methodology will achieve these 
objectives. 
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CHAPTER 3  
[Results and Discussion] 
 
 
 
 
Presented in the form of a full-length manuscript in preparation for future publication 
in a scientific journal 
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3.1 INTRODUCTION  
 
Myosin IIA heavy chain, a subunit of myosin IIA protein, consists of 1960 amino 
acids and is 227kDa in size, with a globular head in amino-terminus and a coiled-
coil tail in carboxy-terminus (Schliwa, 2006). An actin binding site is found in the 
head region, interacting with actin, as well as a light chain binding site present in 
the long tail region (Figure 3.1). Myosin IIA heavy chain is encoded by the MYH9 
gene, which is approximately 110 kilobases long with 41 exons, and is located on 
the long arm of chromosome 22 at position 13.1 (Kopp et al, 2008). It is 
abundantly expressed in the kidney, platelets and liver and in smaller amounts in 
the thymus, spleen, intestine and cochlea. Within the kidney, it is expressed in the 
glomerulus, specifically the podocyte, peritubular capillaries and tubules. Myosin 
IIA heavy chain plays several physiological roles such as cytokinesis, cell motility 
and the maintenance of cell shape (Schliwa, 2006).  
 
 
 
 
 
 
 
 
 
Figure 3.1: Schematic representation of the myosin non-muscle structure 
(Adapted from Straussman et al, 2007; permission in Addendum F) 
 
More than 45 mutations have been found in the MYH9 gene, and implicated in a 
wide range of disorders that have subsequently been grouped and termed the 
MYH9-related disorder. These disorders are characterized by large platelets and 
thrombocytopenia, both present from birth (Schliwa et al, 2006). The link between 
MYH9 polymorphisms and CKD was first discovered in 2008 by Kopp et al in the 
African American population. The role of genes in the development of kidney 
diseases was an immense breakthrough, explaining the aggregation of kidney 
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disease in families and populations that could not be explained solely by other 
known risk factors. Although the exact mechanism by which MYH9 
polymorphisms contributes to the development and progression of non-diabetic 
CKD is unknown; it has been hypothesized that these sequence variants may 
cause aggregation of abnormal myosin and damage to the cytoskeleton of 
podocyte and tubular cells, and rearrangement of the actin cytoskeleton, 
ultimately disrupting the filtration barrier. 
 
SNPs within MYH9 were identified in different regions of the gene, and found to 
be in linkage disequilibrium.  These SNPs were then clustered into groups 
according to linkage disequilibrium blocks (Figure 3.2): extended or E-1 haplotype 
(rs4821480, rs2032487, and rs4821481, rs3752462) (Kao et al, 2008), S-1 
haplotype (rs5750248, rs2413396, rs5750250), F-1 haplotoype (rs16996674, 
rs16996677, rs11912763) (Behar et al, 2010) and L1 haplotype (rs12107, rs7078, 
rs735853, rs5756129) (Freedman et al, 2009). Furthermore, three SNP’s 
(rs4821480, rs5756152, rs12107) exhibited independent evidence for association 
with hypertensive and non-diabetic CKD (Freedman et al, 2009). For this reason, 
the present study investigated the role of rs5756152, rs4821480, and rs12107 in 
CKD and its related clinical traits in a population of Mixed Ancestry origin. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Gene structure and linkage disequilibrium plot of 49 kb of the MYH9 
gene. The three SNPs are shown located in different LD blocks (Taken from 
Freedman et al, 2009; permission in Addendum E) 
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3.2 MATERIALS AND METHODS 
 
Data collection and study population: Participants were members of a cohort 
study conducted in Bellville South, Cape Town, a mixed ancestry Township 
formed in the late 1950s. Eligible participants, selected from 1000 households 
through a multistage random sampling, were invited to take part in a community 
based survey between January 2008 and March 2009, with data collection 
through standardized procedures. All consenting participants received a 
standardized interview and physical examination during which blood pressure 
was measured according to World Health Organisation (WHO) guidelines using a 
semi-automatic digital blood pressure monitor (Rossmax PA, USA) on the right 
arm in sitting position. Other clinical measurements included the body weight, 
height, waist and hip circumferences. All anthropometric measurements were 
performed three times and their average used for analysis. Participants with no 
history of medically diagnosed diabetes mellitus underwent a 75 g OGTT as 
prescribed by the WHO. Blood samples were collected and processed for further 
determinations. Plasma glucose was measured by enzymatic method (Cobas 
6000, Roche Diagnostics), HbA1c was assessed by turbidimetric inhibition 
immunoassay (Cobas 6000, Roche Diagnostics) and urine albumin by 
immunoturbidimetric assay (Cobas 6000, Roche Diagnostics).  
 
CKD definitions and estimation of GFR:  Kidney function was approximated 
through eGFR for which both the 4-variable MDRD equation applicable to 
standardised serum creatinine values, and the CKD-EPI equation were used. An 
eGFR of <60 ml/min was used to define chronic kidney disease (or CKD stage 3-
5). Urinary albumin excretion was quantified in terms of urinary ACR and 
participants ranked according to ACR levels as: normoalbuminuria (ACR<3.4 
mg/mmol), microalbuminuria (3.4<ACR<33.9 mg/mmol) and macroalbuminuria 
(ACR>33.9 mg/mmol). Diabetes status was based on a history of doctor-
diagnosis, a fasting plasma glucose ≥7.0 mmol/l and/or a 2-hour post-OGTT 
plasma glucose >11.1 mmol/l. Hypertension was based on a history of medically 
diagnosed hypertension and/or receiving medications for hypertension or average 
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systolic blood pressure ≥140 mmHg and average diastolic blood pressure ≥90 
mmHg.  
Genotyping of the study population: There is no published data on MYH9 
SNPs and haplotype variations in the mixed ancestry population from South 
Africa. We therefore selected the three SNPs that have been shown to exhibit 
independent evidence for association with CKD (rs4821480, rs575152 and 
rs12107) in prior studies. The SNPs were genotyped using a Taqman genotyping 
assay (Applied Biosystems, USA) on a BioRad Optica (Biorad, Germany) and 
confirmed by sequencing.  
Statistical analysis: Statistical analyses were conducted as described in 
Chapter 2. Descriptive statistics were conducted and general characteristics of 
the study group summarized as count and percentage for dichotomous traits, 
mean and SD or median and 25th-75th percentiles for quantitative traits.  Results 
corresponding to p-values below 5% were described as significant. Traits were 
log-transformed to approximate normality, where necessary, prior to analysis. 
SNPs were tested for departure from HWE expectation via a chi square goodness 
of fit test. LD was estimated using the D’ statistic.  Linear regression models were 
used for the analysis of quantitative traits and logistic regression models for 
dichotomous traits, always assuming additive models for the SNPs.  Using linear 
and logistic models enabled us to adjust all analyses for known confounders as 
specified everywhere in the results. The additive allelic association of each SNP 
with each trait, overall and according to diabetes status was investigated, and 
tested for heterogeneity by adding the interaction term of diabetes and each SNP 
to a model that contained the main effects of diabetes and the relevant SNP. 
Results corresponding to p-values below 5% are described as significant. All 
analyses used the statistical package R (version 2.12.2 [2011-02-25], The R 
Foundation for statistical computing, Vienna, Austria). 
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3.3 RESULTS 
 
3.3.1 Genetic analysis 
 
Conventional PCR was used to run the initial samples of each SNP and the final 
products of the PCR were electrophoretically separated on 2% agarose gel. The 
gel electrophoresis images are available. Figure 3.3 shows the electrophoresed 
products of each of the three SNPs, rs5756152, rs4821480 and rs12107. 
Amplicons were sequenced and analyzed for the presence or absence of 
specified sequence variants. The sequencing results display the three possible 
nucleotide combinations (genotypes) present in that specific SNP. Heterozygous 
refers to the presence of two different nucleotides at a locus, one from each 
parent. Alternatively, two of the same nucleotides at a locus is denoted as 
homozygous. An individual may be homozygous for either of the two nucleotides 
present in the heterozygous state. Homozygosis may be for the allele with a lower 
frequency in a particular population, the minor allele and perhaps the risk allele if 
association is found; or for the allele with the highest frequency, the most 
common genotype in a population, the wild-type. Figure 3.4, 3.5 and 3.6 display 
chromatograms that represent the sequences around each SNP, and the 
corresponding genotypes there were identified in the study population. The 
rs5756152 SNP is an adenine guanine substitution (c.1380+90A>G) located in 
intron 12 of the MYH9 gene (Figure 3.4). Figure 3.5 shows the guanine to 
thymine substitution (c.2977-159G>T) of the rs4821480 SNP, which is located in 
the intron 23 of MYH9 gene. The rs12107 SNP is a cytosine to thymine 
substitution (c.*732C>T) located in exon 41 at the 3’ untranslated region of the 
MYH9 gene. 
 
Subsequently all samples were genotyped using qPCR, using the BioRad 
MiniOpticon. Ready-to-use TaqMan SNP genotyping assay was used for 
detecting MYH9 polymorphisms in individuals included in the study. The 
MiniOpticon was calibrated to use VIC and FAM fluorescent dyes. Figure 3.7, 3.8 
and 3.9 exhibits the allele discrimination scatter plots showing VIC and FAM 
fluorescence results, the amplification of alleles. Each symbol represents an allele 
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that was amplified by qPCR in each sample. Amplified samples tend to cluster 
into groups corresponding to the three genotypes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
Figure 3.3: Conventional PCR products of the three SNPs genotyped on 2% 
agarose gel, stained by EtBr and visualised using ultraviolet light 
transillumination. A: The product of amplification of rs5756152, the arrow 
indicates the product, B: rs4821480 C: rs12107  
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Figure 3.4: Sequencing chromatogram for rs5756152 showing the three 
genotypes obtained in the study population. The arrow indicates the affected 
nucleotide and R represents the presence of both nucleotides (A and G). Colour 
coding of the peaks: green, adenine (A); blue, cytosine (C); black, guanine (G); 
red, thymine (T).  
Homozygous GG
Heterozygous GA
Homozygous AA
Homozygous - GG 
Heterozygous - AG 
Homozygous - AA 
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Figure 3.5: Sequence chromatogram for rs4821480. The arrow indicates the 
affected nucleotide and K represents the presence of both nucleotides (G and T). 
Colour coding of the peaks: green, adenine (A); blue, cytosine (C); black, guanine 
(G); red, thymine (T).  
 
 
Homozygous - GG 
Heterozygous - GT 
Homozygous - TT 
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Figure 3.6: Sequence chromatogram for rs12107. Reverse primers were used. 
The arrow indicates the complementary base of the affected nucleotide and Y 
represents the presence of C and T, thus the G and A on the sense strand. 
Colour coding of the peaks: green, adenine (A); blue, cytosine (C); black, guanine 
(G); red, thymine (T).  
Homozygous - CC 
Homozygous - TT 
Heterozygous - CT 
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Figure 3.7: Allele discrimination scatter plot showing amplification of alleles of 
SNP rs5756152. Each symbol represents an allele that was amplified by qPCR in 
each sample. Diamond – no fluorescence, negative, Square - only VIC, minor 
allele (G/G), Circle – only FAM, wild-type (A/A), Triangle – VIC and FAM, 
heterozygous (G/A). *RFU – relative fluorescence units 
 
 
 
 
 
 
 
 
Figure 3.8: Allele discrimination scatter plot showing amplification of alleles of 
SNP rs4821480. Each symbol represents an allele that was amplified by qPCR in 
each sample. Diamond – no fluorescence, negative, Square - only VIC, minor 
allele (T/T), Circle – only FAM, wild-type (G/G), Triangle – VIC and FAM, 
heterozygous (T/G). *RFU – relative fluorescence units 
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Figure 3.9: Allele discrimination scatter plot showing amplification of alleles of 
SNP rs12107. Each symbol represents an allele that was amplified by qPCR in 
each sample. Diamond – no fluorescence, negative, Square - only VIC, minor 
allele (A/A), Circle – only FAM, wild-type (G/G), Triangle – VIC and FAM, 
heterozygous (A/G). *RFU – relative fluorescence units 
 
3.3.2 General Characteristics: 
 
Baseline characteristics of participants are summarized in Table 3.1 and 3.2, by 
gender and CKD status respectively. Generally there were more females than 
men in the study, 566 and 162 respectively.  The median age was not 
significantly different between the women and men, 53 vs 53, respectively.  
Significant differences were observed between males and females in serum 
creatinine (p <0.001), eGFR (p <0.001), systolic blood pressure (p = 0.003) and 
diastolic blood pressure (p = 0.021), with males demonstrating higher values than 
females (Table 3.1). The prevalence of CKD (eGFR ≤ 60 ml/min/1.73 m2) was 
29.6%, 206 participants were stage 3 and 8 were stage 4, while stage 2 had the 
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highest participant number (407). As illustrated in Table 3.2, the CKD prevalence 
increased with age, (p < 0.001). By selection, serum creatinine was significantly 
higher in CKD-affected participants (p <0.001), with a corresponding lower eGFR 
(p <0.001). Notably, was the considerably high prevalence of diabetes and 
hypertension with 58 CKD cases having both diabetes and hypertension; 78 
having hypertension, but no diabetes; 20 having diabetes but no hypertension 
and 58 having neither diabetes nor hypertension.  
 
 
Table 3.1: General characteristics of participants, stratified by gender. P-values 
are for the difference between groups. Significant p-values are highlighted. 
 Trait  Female Male P-value* 
Number 566 162  
Age, median (IQR) 53 (43-65) 56 (44-68) 0.181 
Serum Creatinine (umol/l) 78 (68-89) 93 (83-105) < 0.001 
eGFR (ml/min/1.73m
2
) 68 (56-80) 75 (63-86) < 0.001 
GFR stage, n (%)   0.017 
4 7 (1) 1 (1)  
3 175 (31) 31 (19)  
2 304 (54) 103 (64)  
1 76 (14) 27 (17)  
CKD.MDRD (GFRd) 182 (32) 32 (20) 0.002 
FBG (mmol/l) 5.6 (5.0-6.5) 5.4 (5.0-6.6) 0.459 
Post FBG (mmol/l) 6.9 (5.7-8.6) 6.3 (5.3-8.4) 0.057 
WHO diagnosis   0.399 
Normal 287 (51) 86 (53)  
DM 88 (16) 20 (12)  
IFG 21 (4) 3 (2)  
IFG+IGT 23 (4) 6 (4)  
IGT 76 (14) 19 (12)  
Known DM 67 (12) 28 (17)  
SBP (mmHg) 119 (108-132) 125 (115-135) 0.003 
DBP (mmHg) 73 (66-82) 77 (69-84) 0.021 
HPT, yes (%) 246 (44) 64 (40) 0.368 
*Significant p-value < 0.005. Abbreviations: IQR, Inter Quartile Range; eGFR, Estimated 
Glomerular Filtration Rate; CKD, Chronic Kidney Disease; MDRD, Modification of Diet in Renal 
Disease; FBG, Fasting Blood Glucose; WHO, World Health Organization; DM, Diabetes Mellitus; 
IFG, Impaired Fasting Glucose; IGT, Impaired Glucose Tolerance; SBP, Systolic Blood Pressure; 
DBP, Diastolic Blood Pressure; HPT, Hypertension. 
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Table 3.2: General characteristics of participants, stratified by CKD status. P-
values are for the difference between groups, adjusted for age and gender, where 
possible. Significant p-values are highlighted. 
 Trait CKD CASE CONTROL P-value* 
Number 214 510  
Gender, male (%) 32 (15) 130 (25) 0.001 
Age, median (IQR) 66 (58-74) 48 (39-58) < 0.001 
Urine creatinine (umol/day) 7.2 (4.8-11.0) 8.0 (5.3-12.1) 0.004 
Urine microalbumin (µg/ml) 5.0 (3.0-15.2) 4.1 (3.0-10.4) 0.395 
Serum creatinine (umol/l) 97 (90-112) 75 (66-83) < 0.001 
ACR (mg/mmol) 0.82 (0.47-1.97) 0.70 (0.39-1.50) 0.787 
HbA1c (%) 6.0 (5.6-6.5) 5.8 (5.5-6.2) 0.014 
FBG (mmol/l) 6.0 (5.0-7.0) 5.4 (5.0-6.3) 0.087 
Post FBG (mmol/l) 7.5 (6.0-9.0) 6.5 (5.5-8.3) 0.166 
SBP (mmHg) 126 (115-141) 118 (108-130) 0.150 
DBP (mmHg) 74 (67-83) 74 (66-82) 0.059 
eGFR (mL/min/1.73m
2
) 53 (47-56) 76 (69-88) < 0.001 
DM, yes (%) 78 (36) 125 (25) 0.827 
HPT, yes (%) 136 (64) 173 (34) 0.042 
DM Yes, HPT Yes (%)  58 (27) 74 (15) 0.149 
* Significant p-value < 0.005. Abbreviations: IQR, Inter Quartile Range; sACR, Albumin/Creatinine 
Ratio; HbA1c, Glycated Hemoglobin; FBG, Fasting Blood Glucose; SBP, Systolic Blood Pressure; 
DBP, Diastolic Blood pressure; eGFR, Estimated Glomerular Filtration Rate; DM, Diabetes 
Mellitus; HPT, Hypertension. 
 
 
3.3.3 Genotype distribution: 
 
Linkage disequilibrium analysis was performed in participants with and without CKD. 
SNP rs5756152 was in LD with both rs4821480 and rs12107, but LD was strongest 
but not complete with rs4821480 with D’ = 0.71 and 0.66 in cases and controls 
respectively. On the other hand, rs4821480 and rs12107 were not in LD, with D’ = 
0.02 and 0.14 in cases and controls respectively (Table 3.3). Table 3.4 shows that all 
SNPs were in HWE in both cases and controls, except rs4821480 in control subjects 
(HWE = 0.007). The frequency distributions, both genotype and allele, did not differ 
significantly between the two groups. The A allele of rs575152, G allele of rs4821480 
and G allele of rs12107 and were the most frequent in both cases and controls, 
deeming these the wild type alleles. The genotype distributions comparison between 
genders (Table 3.5) yielded slightly different results. Both genotype and allele 
frequency distribution did not differ significantly between rs5756152 and rs12107; 
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however a significant difference (p = 0.040) was seen for the G/G haplotype for 
rs4821480 between males and females, with a higher frequency in males (47%). The 
T allele frequency for rs4821480 between males and females was notably significant 
(p 0.010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Minor allele frequencies of the three selected SNPs 
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Table 3.3: Linkage disequilibrium data between the three selected SNPs. A: 
rs5756152 compared to rs4821480 and rs12107 in participants with CKD. B: 
rs4821480 and rs12107 LD determination in CKD participants. C: rs5756152 
compared to rs4821480 and rs12107 in participants without CKD. D: rs4821480 and 
rs12107 LD determination in non-CKD participants.  
 
 
 
A: CKD: YES rs4821480 rs12107 
rs5756152 D 0.05 0.02 
rs5756152 D’ 0.71 0.23 
rs5756152 Corr. 0.34 0.15 
rs5756152 x
2 50.25 9.26 
rs5756152 P-value 0.0000 0.0023 
rs5756152 n 214 214 
 
B: CKD: YES rs12107 
rs4821480 D 0.00 
rs4821480 D’ 0.02 
rs4821480 Corr. 0.01 
rs4821480 x
2 0.07 
rs4821480 P-value 0.7921 
rs4821480 n 214 
 
 
 
 
 
 
 
 
 
 
 
 
*Significant p-values are highlighted.  
 
 
 
C: CKD: NO rs4821480 rs12107 
rs5756152 D 0.06 0.02 
rs5756152 D’ 0.66 0.16 
rs5756152 Corr. 0.33 0.11 
rs5756152 x
2 110.62 12.15 
rs5756152 P-value <0.0001 0.0005 
rs5756152 n 510 510 
D: CKD: NO rs12107 
rs4821480 D -0.01 
rs4821480 D’ 0.14 
rs4821480 Corr. -0.07 
rs4821480 x
2 4.39 
rs4821480 P-value 0.0361 
rs4821480 n 510 
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Table 3.4: Genotype distributions, minor allele frequencies, and unadjusted p-values 
for comparing genotype distributions between CKD groups, additive allelic effects 
between CKD groups.  HWE p-values are from exact tests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Abbreviation: HWE, Hardy Weinburg Equilibrium 
 
 
 
 
 
 
 
 
 
  CKD CASE CON P-value 
n 214 510  
rs5756152 
A/A 168 (0.79) 375 (0.74) 0.438 
A/G 41 (0.19) 126 (0.25)  
G/G 5 (0.02) 9 (0.02)  
G 51 (0.12) 144 (0.14) 0.115 
HWE 0.192 0.855  
    
rs4821480 
G/G 88 (0.41) 199 (0.39) 0.226 
G/T 94 (0.44) 215 (0.42)  
T/T 32 (0.15) 96 (0.19)  
T 158 (0.37) 407 (0.40) 0.141 
HWE 0.463 0.007  
    
rs12107 
G/G 117 (0.55) 283 (0.55) 0.303 
G/A 87 (0.41) 191 (0.37)  
A/A 10 (0.05) 36 (0.07)  
A 107 (0.25) 263 (0.26) 0.808 
HWE 0.275 0.644  
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Table 3.5: Genotype distributions, minor allele frequencies, and unadjusted p-
values for comparing genotype distributions between genders. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  *Significant p-values are highlighted. 
 
3.3.4 Genotype associations: 
 
In additive allelic models that were adjusted for age and gender, only rs5756152 
demonstrated an association with CKD, whereby each G allele of rs5756152 
increased eGFR by 3.67 ml/min/1.73 m2 (95% CI: 1.29-6.05), p = 0.003, reduced 
serum creatinine by 4.5% (95%CI: 1.7-7.4%), p = 0.002 and added 0.51 mmol/L 
(95% CI: 0.06-0.96) to fasting blood glucose, p = 0.028 (Table 3.6). Interactive 
models were used to test additive allelic effect on the traits between those 
participants with diabetes and those with hypertension. It was the effect on the 
traits between the diabetic group and those without diabetes mellitus that showed 
significant results.  Seven SNP-trait pairs differed significantly between the 
diabetic group and those without diabetes. The results are summarized Table 3.7, 
starting with the interaction p-values.  It was found that in each of the combinations 
   Female Male P-value 
n 566 162  
rs5756152 
A/A 423 (0.75) 124 
(0.77) 
0.479 
A/G 130 (0.23) 37 (0.23)  
G/G 13 (0.02) 1 (0.01)  
G 156 (0.14) 39 (0.12) 0.414 
    
rs4821480 
G/G 211 (0.37) 76 (0.47) 0.040 
G/T 247 (0.44) 66 (0.41)  
T/T 108 (0.19) 20 (0.12)  
T 463 (0.41) 106 
(0.33) 
0.010 
    
rs12107 
G/G 304 (0.54) 97 (0.6) 0.372 
G/A 224 (0.4) 57 (0.35)  
A/A 38 (0.07) 8 (0.05)  
A 300 (0.27) 73 (0.23) 0.142 
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of trait and SNP showing a difference, the effect was significant in the DM group, 
but not in the normal group. The effect sizes in the DM group, with 95% 
confidence intervals, for the listed allele are also given. In the DM group, with each 
G allele of rs5756152, serum creatinine decreased by 10%, eGFR increased by 
8.8 ml/min/1.73m2, and FBG and post FBG increased by 1.3 mg/dl and 2.2 mg/dl 
respectively.  Also in the DM group, each rs4821480 T allele increased eGFR with 
4.9 ml/min/1.73m2 whereas each rs12107 A allele reduced FBG and Post FBG by 
0.9 mg/dl and 2.0 mg/dl respectively. 
 
Table 3.6: Genotype association and additive allelic association p-values between 
traits and SNPs. Adjusted for age and gender 
 
*Significant p-value < 0.05. Abbreviations: eGFR, Estimated Glomerular Filtration Rate; CKD, Chronic 
Kidney Disease; MDRD, Modification of Diet in Renal Disease; FBG, Fasting Blood Glucose; SBP, 
Systolic Blood Pressure; DBP, Diastolic Blood Pressure. 
 
Table 3.7: Significant SNP-trait pairs in additive allelic associations between DM and 
non DM groups. The interaction p-value, and the effect (95% CI) of each allele on 
that trait, in the DM group. 
*Significant p-value <0.05. Abbreviations: **CI: Confidence Interval. DM: Diabetes Mellitus.  
eGFR: Estimated Glomerular Filtration Rate. FBG: Fasting Blood Glucose.  
 Genotype Additive allelic 
  rs5756152 rs4821480 rs12107 rs5756152 rs4821480 rs12107 
Age 0.582 0.804 0.663 0.617 0.695 0.402 
Serum Creatinine (mg/dl) 0.010 0.181 0.724 0.002 0.139 0.998 
eGFR (ml/min/1.73m
2
) 0.010 0.111 0.652 0.003 0.064 0.986 
CKD.MDRD 0.226 0.303 0.438 0.115 0.141 0.808 
FBG (mg/dl) 0.087 0.855 0.292 0.028 0.593 0.125 
Post FBG (mg/dl) 0.502 0.422 0.217 0.247 0.642 0.114 
SBP (mmHg) 0.528 0.637 0.935 0.613 0.389 0.717 
DBP (mmHg) 0.784 0.159 0.176 0.493 0.097 0.918 
Interaction 
P-value 
Trait Allele Effect (95% CI) in DM 
0.0426 Serum Creatinine (%) rs5756152 G -10.0 (4.9-14.8) 
0.0057 eGFR (ml/min/1.73m
2
) rs5756152 G 8.8 (4.5-13.2) 
0.0013 FBG (mg/dl) rs5756152 G 1.3 (0.7-2.0) 
<0.0001 Post FBG (mg/dl) rs5756152 G 2.2 (1.3-3.1) 
0.0069 eGFR (ml/min/1.73m
2
) rs4821480 T 4.9 (2.0-7.9) 
0.0050 FBG (mg/dl) rs12107 A -0.9 (0.4-1.4) 
<0.0001 Post FBG (mg/dl) rs12107 A -2.0 (1.3-2.7) 
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3.4. DISCUSSION 
 
The results of this study provide evidence that SNP’s in the MYH9 gene are 
associated with eGFR levels in type 2 diabetic mixed ancestry subjects from 
South Africa, with the reference alleles of rs5756152 and rs4821480 increasing 
the eGFR. Although the E-1 haplotype has previously been shown to confer all 
the excess burden of diabetes-unrelated ESRD in African Americans (Kopp et al, 
2008; Nelson et al, 2010), the strongest association with eGFR was observed 
with rs5756152 and to a lesser extent by the E-1 rs4821480 after performing 
interaction model analysis. A serum creatinine effect was only seen with the G 
allele of rs5756152, decreasing creatinine levels by 10% (Table 3.7). This 
positive association has not been seen between this SNP and serum creatinine 
in previous research. An intriguing finding in this study was the association with 
the genotyped SNPs on blood glucose levels. The G allele of SNP rs5756152 G 
increased blood glucose levels while the A allele of rs12107 decreased blood 
glucose levels (Table 3.7).   Despite the identification of disease susceptible 
MYH9 SNPs, the disease causal mechanism remains largely unknown. It is 
known that the non-muscle myosin protein is abundantly expressed in the kidney, 
platelets and liver and in smaller amounts in the thymus, spleen, intestine and 
cochlea. Within the kidney, it is expressed in the podocytes which are highly 
specialized cells, with the ability to ultra-filter blood and support glomerular 
capillary pressures (Perry et al, 2006; Saleem et al, 2008). The MYH9 gene, 
specifically the E-1 haplotype, has been shown to modulate the genetic effect of 
FRMD3 for diabetes susceptibility (Freedman et al, 2011). In view of our results, 
it is possible that the MYH9 exerts this effect through gene-gene interaction in the 
regulation of blood glucose levels. It is not clear why the two SNP’s had opposing 
effects on blood glucose levels, we speculate that their different effects on 
glucose levels are likely cancelling each other if both are present in an individual, 
consequently the weak association with type 2 diabetes-associated ESRD. 
 
Populations with an African ancestry, such as African Americans, have long been 
shown to be prone to the development of kidney diseases with a poorer 
prognosis compared to their European counterparts (Freedman et al, 1995). 
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These discrepancies have often been linked to lifestyle, social-economic status 
and clinical factors such as poor blood glucose or blood pressure control. In 
2008, two studies took advantage of the differences in kidney disease prevalence 
and its cumulative lifetime risk (2.1% vs 7.5%, respectively) between Americans 
of European and African origin, and identified SNPs in the MYH9 gene which 
conferred most or nearly all of the increased risk for non-diabetic kidney disease 
in African Americans (Kao et al, 2008; Kopp et al, 2008). The MYH9 SNPs were 
clustered into groups according to linkage disequilibrium blocks: the E-1 
haplotype (rs4821480) (Kao et al, 2008; Kopp et al, 2008), S-1 haplotype, F-1 
haplotype (Behar et al, 2010) and L1 haplotype (rs12107) (Freedman et al, 
2009). In this study, we genotyped three SNP’s (rs5756152, rs4821480 and 
rs12107) that have been shown to exhibit independent evidence for association 
with non-diabetic ESRD (Freedman et al, 2009). This study is different from the 
previous reports as it demonstrates an early association between MYH9 
polymorphisms and renal phenotypes, and describes the effect of MYH9 
polymorphisms in a community based cohort as opposed to clinically diagnosed 
ESRD. These findings, and those previously published, suggest that the MYH9 
gene may have a broader genetic risk effect on different types of kidney diseases 
 
 
Non-communicable diseases are the leading cause of death in the world, 
responsible for 59% of the 57 million deaths that occurred in 2008 (Aiwan et al, 
2010). Thirty-six million of these deaths were attributed to cardiovascular 
disease, diabetes, cancers and chronic respiratory disease. Underlying all this is 
the much less appreciated epidemic of CKD, which in return brings with it a huge 
burden of CVD and ESRD (Davids, 2007). Our study showed that 29.6% of the 
population in Bellville South had CKD, of which 96.3% had an eGFR of <60 
ml/min/1.73m2 (Stage 3 CKD). This figure is significantly higher than the reported 
prevalence in developed countries like the USA (13.1%) (Huda, Alam and 
Rashid, 2012) and is likely explained by the significantly older age of participants 
with CKD. The lack of functioning registries in sub-Saharan Africa, including 
South Africa, has resulted in a lack of reliable statistics, but the impression is that 
the prevalence of CKD is at least 3-4 times more frequent than in developed 
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countries (Naicker, 2009; Ainah, 2010). The last report from the South African 
Dialysis and Transplant Registry was in 1994 and revealed a prevalence of 99 
patients per million (3399 patients) on renal replacement therapy (reviewed by 
Davids, 2007). However, this only reports the incidence of patients with ESRD, 
on treatment and excludes the larger proportion of patients with CKD (Stages 3 
and 4). 
 
The development of CKD is strongly associated with hypertension and type 2 
diabetes. Indeed, we observed a high prevalence of diabetes and hypertension in 
subjects with CKD. In Africa, hypertension is a major cause of CKD and 
conversely, secondary hypertension is most commonly initiated by the presence 
of CKD (Sinclair et al, 1987). In our population 64% of subjects with CKD also 
had hypertension compared to 34% in subjects without CKD. This figure is similar 
to those quoted in the USA, where hypertension is the number two cause of 
ESRD, following diabetes, and is a co-morbid condition in approximately 61-66% 
of those with eGFR <60 ml/min/1.73m2 (Bethesda, 2011). Hypertension affects 
approximately 25% of the adult population and is a cause of CKD in 21% of 
patients on renal replacement therapy in the South African Registry (Variava et 
al, 1990; reviewed by Naicker, 2009). For these reasons, treatment of 
hypertension is a very important factor in CKD and CVD risk reduction strategy. 
Co-existence of hypertension is associated with more rapid progression of CKD 
and several studies have indicated that treating hypertension in patients with 
CKD and proteinuria may slow the decline in GFR and progression of CKD (Maki 
et al, 1995; reviewed by He and Whelton, 1999; Jafar et al, 2003; Casas et al, 
2005).  
 
Currently approximately 366 million individuals suffer from type 2 diabetes, and 
future predictions indicate that this number will surge to approximately 522 million 
by 2030 (International Diabetes Federation, 2011). The observed prevalence of 
diabetes in our population is 28.4%; higher than the world diabetes prevalence of 
6.4% in 2010 among adults aged 20-79 years (Shaw, Sicree and Zimmet, 2010).  
Diabetes mellitus type 2 is becoming a global health problem due to several 
factors, including aging, urbanization, increasing prevalence of obesity and 
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physical inactivity (Wild et al, 2004). One third of diabetic patients will eventually 
develop CKD due to diabetic nephropathy (Bethesda, 2007).  Diabetic 
nephropathy is characterized by proteinuria, and the earliest sign is considered to 
be microalbuminuria (Inomato et al, 1989). Traditional risk factors such as 
hypertension, hyperlipidaemia and smoking need to be managed in patients with 
co-existing diabetes mellitus as they contribute to the increased cardiovascular 
risk and worsening of renal failure. As highlighted before, our study cohort 
demonstrated that these factors strongly correlated with CKD.  
 
To our knowledge, this is the first study in the mixed ancestry population of South 
Africa providing detailed genetic analysis of kidney diseases. A major limitation of 
this study pertains to the measurements of the general characteristics of the 
subjects. Blood glucose measurements were not repeated in asymptomatic 
subjects who were found to have diabetes, while according to the WHO type 2 
diabetes diagnosis procedure requires at least one further test on a subsequent 
day (WHO, 2003). Urine samples to determine albumin levels were only collected 
and analysed once, with the KDIGO guidelines stating that albuminuria can only 
be diagnosed on two to three separate urine collections.  
 
In conclusion, SNPs rs5756152 and rs4821480 are associated with early kidney 
diseases in the mixed ancestry population of South Africa with type 2 diabetes 
whilst rs12107 is associated with glucose metabolism. Our findings and other 
studies suggest that the MYH9 gene may have a broader genetic risk effect on 
different types of kidney diseases.  The findings of this study have important 
public health implications. Strong and specific genetic associations would allow 
for race specific screening, allowing for education on healthy living, delaying the 
onset of CKD as well as allowing for early implementation of appropriate 
treatment, with the hope of preventing disease progression. This would ease a 
large burden of dialysis patients of both state and private hospitals. This is the 
first genetic screening in the mixed race population of South Africa for CKD – a 
small step in a confidently long future of genetic screening in South Africa.  
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3.5. RECOMMENDATION FOR FUTURE STUDIES  
 
This study was unique in the fact that it was a community based cohort 
describing MYH9 polymorphisms and their associations with early renal 
phenotypes, as opposed to clinically diagnosed ESRD. On the strength of these 
findings, the inclusion of ESRD-diagnosed patients in the same mixed ancestry 
population in a future study would allow for comparisons to be made between the 
significance and strength of the effect of the MYH9 polymorphisms on early stage 
CKD and ESRD. Between 20%-40% of patients with diabetes will ultimately 
develop DN (Dronavalli, Duka and Bakrus, 2008) and diabetes is the leading 
cause of ESRD (Bethesda, 2011). The DM prevalence in South Africa and the 
significant findings in this study of the MYH9 polymorphisms’ effect on diabetic 
individuals further substantiate the inclusion of ESRD individuals in future 
studies.  
 
There is a lack of data mapping of the admixture ancestry markers of this mixed 
ancestry population. Although MYH9 risk alleles found in the African American 
population are highly prevalent in populations with an African ancestry including 
the indigenous San and Bantu-South Africans (Oleksek et al, 2010), suggesting 
that the identified SNPs in the African American population will be prevalent in 
this population, it may be possible that there are other SNPs within the MYH9 
gene that may show a significance. In this study, rs5756152 showed the 
strongest association with renal phenotypes; however it must be established if 
other SNPs within the MYH9 gene prove otherwise. In addition, it is 
recommended that these future studies include the APOL1 gene. APOL1 has 
recently been found to have stronger association with kidney diseases than 
polymorphisms within the MYH9 gene in African Americans. The APOL1 gene 
was mapped in chromosome 22, near the MYH9 locus, with the two risk alleles, 
G1 and G2, overlapping the E-1 haplotype in the MYH9 gene by 89% and 76% 
respectively (Genovese et al, 2010). Suggesting functionality, the G1 and G2 
polymorphisms alter amino acid sequence of the encoded protein, something the 
MYH9-CKD association lacks. APOL1 polymorphisms have been found to be 
strongly associated with FSGS, H-ESRD and HIVAN (Genovese et al, 2010; 
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Kopp et al, 2010). Importantly, the APOL1-mediated kidney disease risk showed 
an autosomal-recessive inheritance rather than an additive pattern that is typical 
of most common complex disease. Although there still remains no evidence that 
APOL1 polymorphisms are strongly associated with CKD and data from the 
human protein atlas suggest that APOL1 is not even expressed in the glomeruli 
(Johnstone et al, 2011), the inclusion of G1 and G2 SNPs from the APOL1 gene 
would have been broadened the study.  
 
The ancestry contribution in the mixed ancestry population needs to be 
considered in this study. The South African mixed ancestry population forms a 
unique, highly admixed population, resulting from the encounter of different 
people from Africa, Europe, and Asia, and more specifically, five different 
parental populations; Khoisan, Bantus, Europeans, Indians, and Southeast 
Asians (Quintana-Murci et al, 2010). The importance is the different contributions 
from the parental populations. The mixed race population in this study was 
confined to one, long-standing community, decreasing the likelihood of 
unbalanced genetic admixture between the participants. A comparison study 
could be done between the mixed ancestry groups within the different regions of 
South Africa, who undoubtedly have dissimilar ancestry contributions. 
Furthermore, due to the heterogeneity of the mixed race population, the inclusion 
of a homogenous group such as black South Africans warrants investigation.   
 
Finally, to broaden the knowledge of the effect of the MYH9 gene polymorphisms 
in the mixed ancestry population, larger studies in the future should include 
biopsy-confirmed HIVAN and FSGS participants, both highly prevalent in South 
Africa and both important in ESRD progression. HIV infected individuals, a 
prevalent finding in South Africa, are at risk of developing both HIVAN and 
secondary FSGS (Schrier, 2010). The E-1 haplotype of the MYH9 gene has been 
associated with both HIVAN And FSGS in the African American population (Kopp 
et al, 2008; Freedman et al, 2009), opening the doors for this to be investigated 
in the mixed ancestry population in South Africa.  
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ADDENDUM A – ETHICS CLEARANCE 
 
01 August 2012         MAILED 
 
Prof RT Erasmus 
Department of Pathology 
Division Chemical Pathology 
9
th
 Floor 
Tygerberg Hospital 
 
 
Dear Prof Erasmus 
 
Occurrence of CKD and its association with the MYH9 gene in a South African population 
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It is a pleasure to inform you that a review panel of the Health Research Ethical Committee has 
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period of one year from this date.  
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mentioned project number in ALL future correspondence. You may start with the project. 
Notwithstanding this approval, the Committee can request that work on this project be halted 
temporarily in anticipation of more information that they might deem necessary.  
 
Please note a template of the progress report is obtainable on www.sun.ac.za/rds and should be 
submitted to the Committee before the year has expired. The Committee will then consider the 
continuation of the project for a further year (if necessary). Annually a number of projects may be 
selected randomly and subjected to an external audit.  
 
Translations of the consent document in the languages applicable to the study participants should be 
submitted. 
 
Federal Wide Assurance Number: 00001372 
Institutional Review Board (IRB) Number: IRB0005239 
 
The Health Research Ethics Committee complies with the SA National Health Act No. 61 2003 as it 
pertains to health research and the United States Code of Federal Regulations Title 45 Part 46. This 
committee abides by the ethical norms and principles for research, established by the Declaration of 
Helsinki, the South African Medical Research Council Guidelines as well as the Guidelines for Ethical 
Research: Principles Structures and Processes 2004 (Department of Health). 
 
Please note that for research at primary or secondary healthcare facility permission must still be 
obtained from the relevant authorities (Western Cape Department of Health and/or City Health) to 
conduct the research as stated in the protocol. Contact persons are Ms Claudette Abrahams at 
Western Cape Department of Health (healthres@pgwc.gov.za Tel: +27 21 483 9907) and Dr Hélène 
Visser at City Health (Helene.Visser@capetown.gov.za Tel: +27 21 400 3981). Research that will be 
conducted at any tertiary academic institution requires approval from the relevant hospital manager. 
Ethics approval is required BEFORE approval can be obtained from these health authorities. 
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Approval date: 1 August 2012    Expiry date: 1 August 2013 
 
Yours faithfully, 
 
MRS MERTRUDE DAVIDS 
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ADDENDUM B – MAIN STUDY QUESTIONNAIRE 
 
 
 
 
 
GLUCOSE INTOLERANCE AND DIABETES QUESTIONNIARE 
 
Name of Interviewer: ……………………………. 
 
Date of Interview:  ……./…..../…....    Ref No …… 
 
To the respondent: 
Thank you very much for your willingness to participate in the completion of this 
questionnaire. The information obtained on this questionnaire will provide us with 
information on all the possible health, family, life style and dietary risk factors within your 
house hold that might influence the development of diabetes. This is because many health 
conditions develop slowly over time yet could be prevented if diagnosed early or if pre 
determined. This questionnaire therefore aims at getting information which may be used to 
determine the extent of diabetes and those likely to develop diabetes in the future. The 
questionnaire should not take long and we hope you find it interesting and enjoyable. All 
answers provided will be treated as confidential and anonymous.  
 
Note 
No special knowledge is needed to fill this questionnaire. Please feel free to ask for 
clarification if needed. 
 
Postal Address: ---------------------------------------------------------- 
 
   ---------------------------------------------------------- 
 
   ---------------------------------------------------------- 
 
Residential address: ---------------------------------------------------------- 
 
   ---------------------------------------------------------- 
 
   ---------------------------------------------------------- 
Telephone OR 
Cell phone Contacts: ---------------------------------------------------------- 
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A. PERSONAL DATA 
 
Instructions: 
Please complete the following general information about yourself by ticking in the box next 
to the appropriate answers. Please take your time and read through questions carefully. 
 
1. What is your date of birth?  
 
2. What is your gender?    
                       
                      Male                        Female     
 
3. What is your marital status? 
 
       Married                         Single                   Widowed      
 
     Divorced                         Other      
 
4. How would you describe yourself?  
 
              Black                                 White     
 
            Colored                                Asian  
     
5. What is the highest level of education you have completed? 
(a) Primary School or less  
(b)  High School (Not Completed)  
(c) High School graduate  
(d) College Or Technical College (Not Completed)  
(e) College or Technical College Graduate  
(f) University or technikon (Not Completed0  
(g) University or technikon graduate  
 
6. What is your Profession/Occupation? 
Please state…………………………………………………………………..   
7 How long have you been living in Bellville South? 
 
      Less than 6 Months                      Less than 1 Year    
  
              1-5 Years                                       5 years and above 
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B. FAMILY HEALTH HISTORY 
 
Instructions: 
 
The following questions will tell us about your family health history. Please 
 complete all the questions by placing a tick next to the appropriate answer 
 or writing in the answer. 
 
8. Are you currently on any medication?  Yes                              No   
   
 
9. If Yes, Please list…………………………………………………………… 
………………………………………………………………………………… 
………………………………………………………………………………… 
………………………………………………………………………………… 
 
10. Have you ever been told that you have diabetes? 
 
  Yes                                                                        No       
 
                                
11. Have any of the following in your family ever had or are being treated for   diabetes? 
 
(a)Mother  
                        Yes                                                   No 
 
(b) Father 
                        Yes                                                   No 
 
(c ) Sister(s) 
                        Yes                                                   No 
 
(d) Brother(s) 
                        Yes                                                   No 
 
(e) Husband/Wife 
                        Yes                                                   No 
 
(f) Children 
                        Yes                                                   No 
 
(g) Grandchildren 
                        Yes                                                   No 
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12. Have any of the following extended family members ever suffered or are suffering from 
diabetes? 
 
 (a) Paternal (Fathers Side) 
       (i)  Uncles 
 
                           Yes                                              No    
 
 
(ii) Aunties 
 
                          Yes                                               No 
 
(iii) Grandparents 
 
                         Yes                                                No 
   
   (b) Maternal (mothers Side)  
             (i) Uncles 
 
                               Yes                                                No 
 
            (ii)  Aunties 
 
                              Yes                                                 No 
 
            (iii) Grand Parents 
 
                             Yes                                                  No 
 
 
13. Have you or any of the following ever been treated for heart problems? 
  
(a) Yourself  
                                  Yes                                             No 
 
(b) Spouse 
                                  Yes                                             No 
 
(c) Mother 
                            Yes                                              No 
 
(d) Father 
                                  Yes                                              No   
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(e) Children 
                            Yes                                               No   
                            
(f) Grandparents 
                                 Yes                                                 No 
 
(g) Sisters 
                           Yes                                                 No 
 
(h) Brothers 
                           Yes                                                 No   
 
 
14. Have any of the following ever been treated for High Blood pressure? 
 
      (a) Yourself 
                                 Yes                                                No 
 
      (b) Spouse 
                                 Yes                                                No 
 
      (c) Mother 
                                  Yes                                               No 
 
      (d) Father 
                                  Yes                                               No 
 
      (e) Children 
                                  Yes                                               No 
 
(f) Grandparents         
                                  Yes                                               No 
 
(g) Sisters 
                            Yes                                                No 
 
(h) Brothers  
                            Yes                                                No 
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15. Did either of your natural parents ever die of a heart attack? 
 
  (a) Before the age of 60? 
                              Yes                                               No  
  
  (b) After the age of 60? 
                              Yes                                               No 
 
 
 
 
 
 
                                                                     
 
16.  Have you or any of the following ever been treated for High Cholesterol? 
 
      (a) Yourself 
                        Yes                                                No 
 
(b) Spouse   
                         Yes                                               No 
 
(c) Mother           
                         Yes                                               No 
 
(d) Father 
                         Yes                                               No 
 
(e) Children 
                         Yes                                               No 
                                                               
(f) Grandchildren 
                         Yes                                               No 
 
(g) Brother 
                         Yes                                               No 
 
(h) Sisters 
                          Yes                                               No    
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E.  ALCOHOL USE 
 
22. Have you ever consumed any alcoholic drinks (Wine, Beer, and Spirits)?         
 
     Yes                                                            No   
 
23. Do you still consume alcoholic drinks?  
 
          Yes                                                             No       
 
24. If you consume or consumed alcohol, how old were you when you first   started drinking? 
      Please state.         …………years 
 
25. If you stopped, how old were you when you stopped drinking? 
      Please state.   ……… 
 
26. Which type of alcohol do you or did you drink? 
 
       Wine                   Beer                  Spirits                  
         
                          Others, please indicate………………………   
 
27. When you drink or drank alcoholic drinks, how many drinks or glasses  
     do you or did you consume daily? Indicate the number…..  
          
28. How many days a week do you or did you consume alcohol? 
 
   1-2                        3-4                           5-6             every day 
 
29. Have you or did you ever feel you should cut down your drinking? 
 
      Yes                                                                No       
 
30. Have people ever annoyed you by criticizing your drinking? 
 
      Yes                                                                No        
 
31. Have you ever felt bad about your drinking? 
 
      Yes                                                                No         
 
32. Have you ever had a drink first thing in the morning to steady your nerves or get rid of a 
hangover (Eye Opener) 
 
       Yes                                                               No 
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F.  BODY MEASUREMENTS.         Interviewers Name…………………… 
33. Weight and Height.                    
  
 
34. CALLIPERS MEASUREMENTS   
 
 
 
 
 
 
 
 
 
 
 
 
 
35. CIRCUMFERENCE 
MEASUREMENTS 
36. 
 
 
 
37. BLOOD PRESSURE MEASUREMENTS.  Interviewers Name……… 
                                     
 
 
 
 
 
 
 Body Weight (kg)    
Body height   (cm)    
Body Mass Index    
 
 
Biceps               1 (cm)   
Biceps               2  (cm)   
Biceps               3  (cm)   
Total   
Triceps              1 (cm)   
Triceps              2  (cm)   
Triceps              3  (cm)   
Total   
Sub-Scapular     1  (cm)   
Sub-Scapular     2  (cm)   
Sub-Scapular     3 (cm)   
Total   
Suprailiac          1  (cm)          
Supra-iliac         2 (cm)   
Supra- Iliac        3 (cm)   
Total   
 
 
 
 
Waist Circumference   1   (cm)    
Waist Circumference   2   (cm)    
Waist Circumference   3   (cm)    
Total    
 
 
 
 
 
Hip Circumference            (cm)    
Hip Circumference            (cm)    
Hip Circumference            (cm)    
Total                                   (cm)    
Systolic  Pressure  1  (mmHg)    
Systolic  Pressure  2  (mmHg)    
Systolic  Pressure  3  (mmHg)    
Diastolic  Pressure 1   (mmHg)    
 Diastolic Pressure 2   (mmHg)             
Diastolic  Pressure 3   (mmHg)    
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G. BLOOD ANALYSIS.            
Interviewers Name………………….. 
 
38. (a) Fasting State Measurements 
 
(i) Did subject eat this morning?........... If yes state time………….. 
 
(ii) When did subject eat the last meal last evening?........................... 
 
(iii) Please indicate the time when fasting blood taken……………… 
 
(iv) Please indicate the time when Glucose was given...…………….. 
 
 
 
 
 
 
 
 
 
39. URINALYSIS 
              
 
 
 
 
Pulse   1        (Beat per Minute)    
Pulse   2        (Beat per Minute)    
Pulse   3        (Beat per Minute)    
 
 
Glucose        mmol/l   
Cholesterol   mmol/l   (L=1, N=2, H=3)   
Triglycerides mmol/l  (L=1, N=2, H=3)   
 
 
 
 
 
(b) Post Prandial Measurements 
 
Please indicate time when post pradial blood was taken……. 
 
 
 
Glucose          mmol/l   
Cholesterol    mmol/l   
Triglycerides mmol/l   
Glucose (N=Negative, P= Positive) 
Protein (N=Negative, P=Positive) 
P 
P 
N 
N 
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H.  Researchers Check list. 
 
Please make a tick or cross against each of the following questions 
 
 
1. Were all personal data questions answered?    
 
 
2. Were all Family Health History questions answered?   
 
 
3. Were all questions on Tobacco use answered? 
 
 
4. Were all questions on Alcohol use answered?    
 
 
5. Were all dietary questions answered? 
 
 
6. Were all body measurements carried out? 
 
 
7.  
(a)  Was fasting blood taken? 
 
 
(b) Was Glucose Given? 
 
 
 
8. Was Post Pradial Blood taken?  
 
 
9. Was B.P Taken       
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ADDENDUM C – CONSENT FORM FROM MAIN STUDY 
 
 
  
 
THE BELLVILLE SOUTH DIABETES SURVEY CONSENT FORM  
 
Investigators:  Prof Matsha (CPUT)  
Mr. Shafick Hassan (CPUT)  
Prof Rajiv Erasmus (University of Stellenbosch)  
Mr Soita David Jonah (MTech student) 
 
 
Address: Faculty of Health and Wellness Sciences, Cape  
Peninsula University of Technology (CPUT), Bellville Campus 
Symphony Way, 7535 
 
Chemical Pathology Department, Faculty of Health Sciences, 
University of Stellenbosch (Tygerberg Campus), Tygerberg, 
7505. 
 
Contact Numbers:  Mr SD Jonah – 072 555 8628 
    Mr Hassan – 021 959 6274 
    Prof Erasmus – 021 938 4107 
    Prof Matsha – 021 959 6366  
 
Dear Participant, 
 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the 
study staff or doctor any questions about any part of this project that you do not fully 
understand.  It is very important that you are fully satisfied and that you clearly understand 
what this research entails and how you could be involved.  Also, your participation is entirely 
voluntary and you are free to decline to participate.  If you say no, this will not affect you 
negatively in any way whatsoever.  You are also free to withdraw from the study at any point, 
even if you do initially agree to take part. 
 
This study has been approved by the Committee for Human Research at Cape University of 
Technology and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and 
the Medical Research Council (MRC) Ethical Guidelines for Research. 
 
 
 
What is this research study all about? 
Worldwide new causes of certain diseases or conditions are continuously being discovered 
by research on the cells and molecules of the body.  For research to be carried out on 
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certain diseases it is necessary to first establish the incidence and prevalence of the 
disease. This project aims to determine the incidence and prevalence of diabetes and 
glucose intolerance. Additionally, this project aims to collect genetic material (blood) to 
analyze for certain variants and to store excess material for future research. When a large 
group of patients with similar diseases has been collected, meaningful research into the 
disease processes may become possible. 
 
 
Why have you been invited to participate? 
The prevalence of diabetes of diabetes in South Africa is not well documented and few 
studies have been conducted since 1994. Many subjects with diabetes are unknown to the 
health service, often because they are not yet diagnosed. In order to assess the magnitude 
of the problem, you have been approached to participate in this project to determine the 
incidence of diabetes amongst our adult population. 
 
You have randomly been selected by means of a computer program to participate in the 
above-mentioned study.  Adults of all races, gender, age (between ages 35 and 60 years) 
and weight will be approached as subjects. 
 
What will your responsibilities be? 
The participant will be requested to provide information about his/her medical history, family 
history and information on eating, drinking and smoking habits. Completion of the 
questionnaire will take no longer than 10 minutes. Measurement such as weight, height, 
waist and hip will be done. Fasting Venous Blood will be collected thereafter you will be 
asked to drink a glucose solution (glucose content 75g). After two hours another venous 
blood will be collected. The blood will be used to determine whether you have diabetes or 
glucose intolerance. The other tests that will be determined from your blood sample are: 
Cholesterol and Triglycerides levels. The remainder of the blood sample will be used for 
genetic and future research studies. The DNA may be stored for several years until the 
technology for meaningful analysis becomes available. No pharmaceutical agent 
(medication) will be tested in the study. 
 
 
Will you benefit from taking part in this research? 
You will be notified of your glucose tolerance state or whether you are diabetic by the 
medical nurse or doctor. Thereafter, you will be referred to your local health centre or 
general practitioner for further investigations and treatment. 
In the unlikely event that the research may lead to the development of commercial 
applications, the participant or the participant’s heirs will not receive any compensation, but 
profits will be reinvested into supporting the cause of further research which may bring 
benefits to my/*the participant’s family and to the community, such as health screening, 
medical treatment, educational promotions, etc. 
 
 
Are there any risks involved in my taking part in this research? 
A slight bruising might occur after blood has been drawn from the arm but this will heal 
quickly. After the administration of the glucose solution, you may feel nauseous and dizzy in 
which case you must notify the medical personnel. A medical nurse will be present on all 
occasions. In addition, the research team will be in contact with medical doctors should you 
need emergency care by a medical doctor. 
Who will have access to your medical records? 
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The participant’s identity will be kept confidential throughout.  Information will not be 
associated with the participant’s name.  The research staff will use only a coded number, 
access will be limited to authorized scientists and any scientific publications, lectures or 
reports resulting from the study will not identify me/*the participant. 
 
Some insurance companies may mistakenly assume that taking part in research indicates a 
higher risk for disease.  Thus no information about you or your family will be shared with 
such companies. 
 
Will you or your child be paid to take part in this study and are there any costs 
involved? 
 
You will not be paid to take part in the study, but your transport, if required will be covered 
for each study visit. It is envisaged that you may be hungry since you would have come 
fasting, therefore, biscuits or fruit will be provided. There will be no costs involved for you if 
you take part in the project. 
    
Is there anything else that you should know or do? 
 
You should inform your family practitioner or usual doctor that you are taking part in a 
research study.   
You will receive a copy of this information and consent form for your own records if it is 
requested 
 
 
 
 
DECLARATION BY PARTICIPANT: 
 
I declare that: 
 
I have read or had read to me this information and consent form and that it is written in a 
language with which I am fluent and comfortable. 
I have had a chance to ask questions and all my questions have been adequately answered. 
I understand that taking part in this study is voluntary and I have not been pressurized to 
take part. 
I may choose to withdraw from the study at any time and will not be penalized or prejudiced 
in any way. 
I may be asked to leave the study before it has finished if the study doctor or researcher 
feels it is in my best interests, or if I do not follow the study plan as agreed to. 
 
 
I also consent that my blood may be: 
 Used and stored for future research studies   
 
 Used and discarded               
 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2007 
 
    
Signature of participant________________  Signature of witness_______________ 
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DECLARATION BY THE INVESTIGATOR 
 
 
I (name) ……………………………………………..……… declare that: 
 
I explained the information in this document to (Names of 
participant)………………………………….……… 
I encouraged him/her to ask questions and took adequate time to answer them. 
I am satisfied that he/she adequately understand all aspects of the research, as discussed 
above 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2007. 
 
    
Signature of investigator_______________   Signature of witness_____________ 
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ADDENDUM D – SOLUTIONS 
 
Lysis Buffer- pH 7.4 
31 ml from NH4Cl (1M stock) 
1 ml of KHCO3 (1M stock) 
100µl of EDTA (100mM stock) 
Phosphate Buffered Saline (PBS)- pH 7.4 
0.2 g KCl 
8.0 g NaCl 
0.2 g KH2PO4 
1.15 g NA2HPO4 
Add all components, one at a time to 900 ml of dH2O, then dissolve by adding dH2O 
to 1L,  
 
Nuclear Lysis Buffer (500 ml)- pH 8.2 
11.5 g NaCl 
10 ml Tris (1M stock) 
10 ml EDTA (10mM stock). 
 
1% (w/v) Sodium Dodecyl Sulphate (pH 7. 2) 
1 g of electrophoresis-grade SDS was dissolved in 100 ml dH2O. 
The solution was heated and stirred with a magnet stirrer to assist dissolution. 
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6 M Sodium Chloride (NaCl) 
350.64 g of NaCl was dissolved in 800 ml of dH2O and then the volume was 
adjusted to 1 L with dH2O. 
 
1X Tris EDTA (TE) Buffer 
10 mM Tris (10 ml 1 mM stock) 
1 mM EDTA (2 ml of 0.5M stock) 
Made up to 1 L with dH2O 
 
Ethidium Bromide (EtBr)  Stain (10 mg/ml) 
1 g EtBr in 100 ml dH2O was added together and stored in a dark bottle 
 
Loading Buffer (Bromophenol blue) 
0.2 g (2%) BPB powder 
1 ml (10 mM) of 1M Tris stock (pH 8.0) 
50 ml (50%) Glycerol 
49 ml dH2O 
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NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
July 11, 2012 
 
 
 
This is a License Agreement between Katya Masconi ("You") and Nature Publishing Group 
("Nature Publishing Group") provided by Copyright Clearance Center ("CCC"). The license 
consists of your order details, the terms and conditions provided by Nature Publishing 
Group, and the payment terms and conditions.  
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2985780432620 
License date July 11, 2012 
Licensed content publisher Nature Publishing Group 
Licensed content publication Kidney International 
Licensed content title 
Polymorphisms in the non-muscle myosin heavy chain 9 
gene (MYH9) are strongly associated with end-stage renal 
disease historically attributed to hypertension in African 
Americans 
Licensed content author 
Barry I Freedman, Pamela J Hicks, Meredith A Bostrom, 
Mary E Cunningham, Yongmei Liu et al. 
Licensed content date Jan 28, 2009 
Volume number 75 
Issue number 7 
Type of Use reuse in a thesis/dissertation 
 
Requestor type academic/educational 
Format print and electronic 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
High-res required no 
Figures Figure 1: MYH9 linkage disequilibrium blocks 
Author of this NPG article no 
Your reference number 
 
Title of your thesis / 
dissertation  
The occurance of genetic variations in the MYH9 gene and 
their association with CKD in a mixed South African 
population 
Expected completion date  Dec 2012 
Estimated size (number of 
pages) 
160 
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Total 0.00 USD 
 
Terms and Conditions 
 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce this 
material for this purpose, and for no other use, subject to the conditions below:  
1. NPG warrants that it has, to the best of its knowledge, the rights to license reuse of 
this material. However, you should ensure that the material you are requesting is 
original to Nature Publishing Group and does not carry the copyright of another 
entity (as credited in the published version). If the credit line on any part of the 
material you have requested indicates that it was reprinted or adapted by NPG with 
permission from another source, then you should also seek permission from that 
source to reuse the material.  
2. Permission granted free of charge for material in print is also usually granted for any 
electronic version of that work, provided that the material is incidental to the work 
as a whole and that the electronic version is essentially equivalent to, or substitutes 
for, the print version. Where print permission has been granted for a fee, separate 
permission must be obtained for any additional, electronic re-use (unless, as in the 
case of a full paper, this has already been accounted for during your initial request in 
the calculation of a print run). NB: In all cases, web-based use of full-text articles 
must be authorized separately through the 'Use on a Web Site' option when 
requesting permission. 
3. Permission granted for a first edition does not apply to second and subsequent 
editions and for editions in other languages (except for signatories to the STM 
Permissions Guidelines, or where the first edition permission was granted for free).  
4. Nature Publishing Group's permission must be acknowledged next to the figure, 
table or abstract in print. In electronic form, this acknowledgement must be visible 
at the same time as the figure/table/abstract, and must be hyperlinked to the journal's 
homepage.  
5. The credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX)  
 
Note: For republication from the British Journal of Cancer, the following credit 
lines apply. 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME], advance online publication, day month year 
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6. Adaptations of single figures do not require NPG approval. However, the adaptation 
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should be credited as follows: 
 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
 
Note: For adaptation from the British Journal of Cancer, the following credit 
line applies. 
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication)  
7. Translations of 401 words up to a whole article require NPG approval. Please visit 
http://www.macmillanmedicalcommunications.com for more information. 
Translations of up to a 400 words do not require NPG approval. The translation 
should be credited as follows: 
 
Translated by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication). 
 
Note: For translation from the British Journal of Cancer, the following credit 
line applies. 
Translated by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication)  
We are certain that all parties will benefit from this agreement and wish you the best in the 
use of this material. Thank you. 
Special Terms:  
v1.1  
If you would like to pay for this license now, please remit this license along with your 
payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you 
will be invoiced within 48 hours of the license date. Payment should be in the form of a 
check or money order referencing your account number and this invoice number 
RLNK500854901. 
Once you receive your invoice for this order, you may pay your invoice by credit card. 
Please follow instructions provided at that time. 
 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 
Boston, MA 02284-3006 
 
For suggestions or comments regarding this order, contact RightsLink Customer 
Support: customercare@copyright.com or +1-877-622-5543 (toll free in the US) or +1-
978-646-2777. 
 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable 
license for your reference. No payment is required.  
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